Drug Patents Expiring in 2025
1. Abilify patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7115587 (Pediatric) | OTSUKA | Aripiprazole complex formulation and method |
Jan, 2025
(a month from now) | |
|
US7550445 (Pediatric) | OTSUKA | Aripiprazole complex formulation and method |
Jan, 2025
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Aug 27, 2011 |
| New Indication(I-616) | Nov 19, 2012 |
| New Indication(I-633) | Feb 16, 2014 |
| M(M-137) | Jun 09, 2017 |
| New Indication(I-700) | Dec 12, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 12, 2021 |
| Orphan Drug Exclusivity(ODE-80) | Dec 12, 2021 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 20 September, 2006
Treatment: NA
Dosage: INJECTABLE
How can I launch a generic of ABILIFY before it's drug patent expiration?
More Information on Dosage
ABILIFY family patents
2. Abilify Asimtufii patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8399469 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2025
(6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8338427 | OTSUKA | Methods for administering aripiprazole |
Mar, 2025
(2 months from now) | |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 27 April, 2023
Treatment: Use of aripiprazole in extended release injectable suspension
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
ABILIFY ASIMTUFII family patents
3. Abilify Maintena Kit patent
expiration
ABILIFY MAINTENA KIT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8399469 | OTSUKA PHARM CO LTD | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2025
(6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8338427 | OTSUKA PHARM CO LTD | Methods for administering aripiprazole |
Mar, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Feb 28, 2016 |
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 28 February, 2013
Treatment: Use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
ABILIFY MAINTENA KIT family patents
4. Abraxane patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7820788 (Pediatric) | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Apr, 2025
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-658) | Oct 11, 2015 |
| New Indication(I-676) | Sep 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Sep 06, 2020 |
| Orphan Drug Exclusivity(ODE-52) | Sep 06, 2020 |
| M(M-14) | Dec 06, 2022 |
| Pediatric Exclusivity(PED) | Jun 06, 2023 |
Drugs and Companies using PACLITAXEL ingredient
Market Authorisation Date: 07 January, 2005
Treatment: NA
Dosage: POWDER
More Information on Dosage
ABRAXANE family patents
5. Acetadote patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399445 | CUMBERLAND PHARMS | Acetylcysteine composition and uses thereof |
Aug, 2025
(8 months from now) | |
| US8653061 | CUMBERLAND PHARMS | Acetylcysteine composition and uses thereof |
Aug, 2025
(8 months from now) | |
Drugs and Companies using ACETYLCYSTEINE ingredient
Market Authorisation Date: 23 January, 2004
Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions
Dosage: INJECTABLE
More Information on Dosage
ACETADOTE family patents
6. Admelog Solostar patent expiration
ADMELOG SOLOSTAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8679069 | SANOFI-AVENTIS US | Pen-type injector |
Apr, 2025
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 11, 2020 |
Drugs and Companies using INSULIN LISPRO ingredient
Market Authorisation Date: 11 December, 2017
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
ADMELOG SOLOSTAR family patents
7. Adrenaclick patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10166334 | IMPAX | Medicine injection apparatuses |
Jan, 2025
(a month from now) | |
| US10166344 | IMPAX | Injection needle assembly |
Jan, 2025
(a month from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 25 November, 2009
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
ADRENACLICK family patents
8. Advair Hfa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7500444 | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Jan, 2025
(19 days from now) | |
|
US7500444 (Pediatric) | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Jul, 2025
(6 months from now) | |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 08 June, 2006
Treatment: NA
Dosage: AEROSOL, METERED
More Information on Dosage
ADVAIR HFA family patents
9. Aemcolo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8741948 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(4 months from now) | |
| US8263120 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(4 months from now) | |
| US8529945 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(4 months from now) | |
| US8486446 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 16, 2028 |
Drugs and Companies using RIFAMYCIN SODIUM ingredient
NCE-1 date: 17 November, 2027
Market Authorisation Date: 16 November, 2018
Treatment: Treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults
Dosage: TABLET, DELAYED RELEASE
More Information on Dosage
AEMCOLO family patents
10. Afinitor patent expiration
AFINITOR IPR and PTAB Proceedings
Can you believe AFINITOR received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8410131 | NOVARTIS | Cancer treatment |
Nov, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-630) | Oct 29, 2013 |
| New Chemical Entity Exclusivity(NCE) | Mar 30, 2014 |
| New Indication(I-638) | May 05, 2014 |
| New Indication(I-650) | Apr 26, 2015 |
| New Indication(I-655) | Jul 20, 2015 |
| Pediatric Exclusivity(PED) | Apr 29, 2018 |
| Orphan Drug Exclusivity(ODE) | Apr 26, 2019 |
| Orphan Drug Exclusivity(ODE-11) | May 05, 2018 |
| New Indication(I-724) | Feb 26, 2019 |
| Orphan Drug Exclusivity(ODE-24) | Apr 26, 2019 |
| Orphan Drug Exclusivity(ODE-108) | Feb 26, 2023 |
Drugs and Companies using EVEROLIMUS ingredient
NCE-1 date: 26 October, 2014
Market Authorisation Date: 09 July, 2010
Treatment: Treatment of solid excretory system tumors; Advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib
Dosage: TABLET
How can I launch a generic of AFINITOR before it's drug patent expiration?
More Information on Dosage
AFINITOR family patents
11. Airduo Digihaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9987229 (Pediatric) | TEVA PHARM | Process for preparing a medicament |
Mar, 2025
(2 months from now) | |
|
US9616024 (Pediatric) | TEVA PHARM | Process for preparing a medicament |
Mar, 2025
(2 months from now) | |
| US9463288 | TEVA PHARM | Dry powder inhalation apparatus |
May, 2025
(5 months from now) | |
| US10765820 | TEVA PHARM | Dry powder inhalation apparatus |
May, 2025
(5 months from now) | |
|
US9463288 (Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Nov, 2025
(11 months from now) | |
|
US10765820 (Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Nov, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER
More Information on Dosage
AIRDUO DIGIHALER family patents
12. Airduo Respiclick patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9616024 (Pediatric) | TEVA PHARM | Process for preparing a medicament |
Mar, 2025
(2 months from now) | |
|
US9987229 (Pediatric) | TEVA PHARM | Process for preparing a medicament |
Mar, 2025
(2 months from now) | |
| US9463288 | TEVA PHARM | Dry powder inhalation apparatus |
May, 2025
(5 months from now) | |
| US10765820 | TEVA PHARM | Dry powder inhalation apparatus |
May, 2025
(5 months from now) | |
|
US9463288 (Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Nov, 2025
(11 months from now) | |
|
US10765820 (Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Nov, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2020 |
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER
More Information on Dosage
AIRDUO RESPICLICK family patents
13. Aklief patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8227507 | GALDERMA LABS LP | Ligands that modulate RAR receptors |
Dec, 2025
(1 year, 5 days from now) | |
| US8470871 | GALDERMA LABS LP | Ligands that modulate RAR receptors |
Dec, 2025
(1 year, 5 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 04, 2024 |
Drugs and Companies using TRIFAROTENE ingredient
NCE-1 date: 05 October, 2023
Market Authorisation Date: 04 October, 2019
Treatment: Topical treatment of acne vulgaris; Method of activating rargamma receptor
Dosage: CREAM
More Information on Dosage
AKLIEF family patents
14. Amitiza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8748481 | SUCAMPO PHARMA LLC | Method for treating gastrointestinal disorder |
Sep, 2025
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-670) | Apr 19, 2016 |
| M(M-225) | Apr 26, 2021 |
Drugs and Companies using LUBIPROSTONE ingredient
Market Authorisation Date: 29 April, 2008
Treatment: Method for the long term treatment of chronic constipation in a human subject with irritable bowel syndrome
Dosage: CAPSULE
More Information on Dosage
AMITIZA family patents
15. Amondys 45 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE48960 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months from now) | |
| US9447415 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2026 |
| Orphan Drug Exclusivity(ODE-347) | Feb 25, 2028 |
Drugs and Companies using CASIMERSEN ingredient
NCE-1 date: 25 February, 2025
Market Authorisation Date: 25 February, 2021
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping
Dosage: SOLUTION
More Information on Dosage
AMONDYS 45 family patents
16. Ampyra patent expiration
AMPYRA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8663685 | MERZ PHARMS | Sustained release aminopyridine composition |
Jan, 2025
(a month from now) | |
| US8440703 | MERZ PHARMS | Methods of using sustained release aminopyridine compositions |
Apr, 2025
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 22, 2015 |
| Orphan Drug Exclusivity(ODE) | Jan 22, 2017 |
Drugs and Companies using DALFAMPRIDINE ingredient
NCE-1 date: 22 January, 2014
Market Authorisation Date: 22 January, 2010
Treatment: Improvement of walking in patients with multiple sclerosis (ms)
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
AMPYRA family patents
17. Amrix patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7387793 | TEVA PHARMS INTL | Modified release dosage forms of skeletal muscle relaxants |
Feb, 2025
(2 months from now) | |
Drugs and Companies using CYCLOBENZAPRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 01 February, 2007
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of AMRIX before it's drug patent expiration?
More Information on Dosage
AMRIX family patents
18. Anoro Ellipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7498440 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(4 months from now) | |
| US7439393 | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
May, 2025
(5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8309572 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(4 months from now) | |
| US8183257 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Jul, 2025
(7 months from now) | |
|
US7439393 (Pediatric) | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
Nov, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 18, 2016 |
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| M(M-245) | Jun 09, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient
NCE-1 date: 18 December, 2017
Market Authorisation Date: 18 December, 2013
Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.
Dosage: POWDER
More Information on Dosage
ANORO ELLIPTA family patents
19. Antara (micronized) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8026281 | LUPIN | Treating metabolic syndrome with fenofibrate |
Apr, 2025
(4 months from now) | |
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 18 October, 2013
Treatment: Treating primary hypercholesterolemia and mixed dyslipidemia
Dosage: CAPSULE
How can I launch a generic of ANTARA (MICRONIZED) before it's drug patent expiration?
More Information on Dosage
ANTARA (MICRONIZED) family patents
20. Apidra Solostar patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8679069 | SANOFI AVENTIS US | Pen-type injector |
Apr, 2025
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 24, 2011 |
Drugs and Companies using INSULIN GLULISINE RECOMBINANT ingredient
Market Authorisation Date: 16 April, 2004
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
APIDRA SOLOSTAR family patents
21. Aptiom patent expiration
Can you believe APTIOM received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10702536 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(4 months from now) | |
| US10695354 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(4 months from now) | |
| US11364247 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(4 months from now) | |
| US10675287 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-150) | Aug 27, 2018 |
| New Indication(I-715) | Aug 27, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2018 |
Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient
NCE-1 date: 08 November, 2017
Market Authorisation Date: 08 November, 2013
Treatment: Treatment of partial-onset seizures; Treatment of partial-onset seizures in a patient with refractory partial-onset seizures
Dosage: TABLET
How can I launch a generic of APTIOM before it's drug patent expiration?
More Information on Dosage
APTIOM family patents
22. Arcapta Neohaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6878721 | NOVARTIS | Beta2-adrenoceptor agonists |
Feb, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
Drugs and Companies using INDACATEROL MALEATE ingredient
NCE-1 date: 02 July, 2015
Market Authorisation Date: 01 July, 2011
Treatment: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema
Dosage: POWDER
More Information on Dosage
ARCAPTA NEOHALER family patents
23. Arikayce Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7718189 | INSMED INC | Sustained release of antiinfectives |
Jun, 2025
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-214) | Sep 28, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 28, 2030 |
Drugs and Companies using AMIKACIN SULFATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen
Dosage: SUSPENSION, LIPOSOMAL
More Information on Dosage
ARIKAYCE KIT family patents
24. Armonair Digihaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9616024 (Pediatric) | TEVA PHARM | Process for preparing a medicament |
Mar, 2025
(2 months from now) | |
| US9463288 | TEVA PHARM | Dry powder inhalation apparatus |
May, 2025
(5 months from now) | |
| US10765820 | TEVA PHARM | Dry powder inhalation apparatus |
May, 2025
(5 months from now) | |
|
US10765820 (Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Nov, 2025
(11 months from now) | |
|
US9463288 (Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Nov, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER
More Information on Dosage
ARMONAIR DIGIHALER family patents
25. Armonair Respiclick patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9616024 (Pediatric) | TEVA PHARM | Process for preparing a medicament |
Mar, 2025
(2 months from now) | |
| US10765820 | TEVA PHARM | Dry powder inhalation apparatus |
May, 2025
(5 months from now) | |
| US9463288 | TEVA PHARM | Dry powder inhalation apparatus |
May, 2025
(5 months from now) | |
|
US9463288 (Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Nov, 2025
(11 months from now) | |
|
US10765820 (Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Nov, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2020 |
| New Patient Population(NPP) | Jul 09, 2024 |
| New Strength(NS) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER
More Information on Dosage
ARMONAIR RESPICLICK family patents
26. Astepro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8518919 | MEDA PHARMS | Compositions comprising azelastine and methods of use thereof |
Nov, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 31, 2012 |
| M(M-129) | Aug 30, 2016 |
| New Patient Population(NPP) | Feb 20, 2018 |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 31 August, 2009
Treatment: Treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis
Dosage: SPRAY, METERED
How can I launch a generic of ASTEPRO before it's drug patent expiration?
More Information on Dosage
ASTEPRO family patents
27. Astepro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8518919 | MYLAN SPECIALITY LP | Compositions comprising azelastine and methods of use thereof |
Nov, 2025
(11 months from now) | |
| US9919050 | MYLAN SPECIALITY LP | Compositions comprising azelastine |
Nov, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 31, 2012 |
| M(M-129) | Aug 30, 2016 |
| New Patient Population(NPP) | Feb 20, 2018 |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2008
Treatment: Treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis
Dosage: SPRAY, METERED
How can I launch a generic of ASTEPRO before it's drug patent expiration?
More Information on Dosage
ASTEPRO family patents
28. Astepro Allergy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8518919 | BAYER HLTHCARE | Compositions comprising azelastine and methods of use thereof |
Nov, 2025
(11 months from now) | |
| US9919050 | BAYER HLTHCARE | Compositions comprising azelastine |
Nov, 2025
(11 months from now) | |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 June, 2021
Treatment: Otc use: allergy symptom reliever; Temporary relief of these symptoms due to hay fever or other upper respiratory allergies: nasal congestion, runny nose, sneezing and itchy nose
Dosage: SPRAY, METERED
How can I launch a generic of ASTEPRO ALLERGY before it's drug patent expiration?
More Information on Dosage
ASTEPRO ALLERGY family patents
29. Auvi-q patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7731690 | KALEO INC | Devices, systems and methods for medicament delivery |
Jan, 2025
(30 days from now) | |
| US8016788 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2025
(3 months from now) | |
| US10335549 | KALEO INC | Devices, systems and methods for medicament delivery |
Apr, 2025
(4 months from now) | |
| US9149579 | KALEO INC | Devices, systems and methods for medicament delivery |
Jul, 2025
(7 months from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 17 November, 2017
Treatment: Method of treating allergic reaction via injection
Dosage: SOLUTION
More Information on Dosage
AUVI-Q family patents
30. Baxdela patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9539250 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8969569 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(9 months from now) | |
| US8648093 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 19, 2022 |
| New Indication(I-815) | Oct 24, 2022 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 19, 2027 |
Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient
NCE-1 date: 19 June, 2026
Market Authorisation Date: 19 June, 2017
Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults
Dosage: TABLET; POWDER
More Information on Dosage
BAXDELA family patents
31. Belviq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8697686 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride |
Dec, 2025
(1 year, 4 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8980881 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
Dec, 2025
(1 year, 4 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2017 |
Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient
NCE-1 date: 27 June, 2016
Market Authorisation Date: 27 June, 2012
Treatment: Method for chronic weight management by controlling weight gain
Dosage: TABLET
More Information on Dosage
BELVIQ family patents
32. Belviq Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8697686 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride |
Dec, 2025
(1 year, 4 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8980881 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
Dec, 2025
(1 year, 4 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2017 |
Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient
NCE-1 date: 27 June, 2016
Market Authorisation Date: 15 July, 2016
Treatment: Method for chronic weight management by controlling weight gain
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
BELVIQ XR family patents
33. Bepreve patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8784789 | BAUSCH AND LOMB INC | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
Jan, 2025
(28 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 08, 2014 |
Drugs and Companies using BEPOTASTINE BESILATE ingredient
NCE-1 date: 08 September, 2013
Market Authorisation Date: 08 September, 2009
Treatment: NA
Dosage: SOLUTION/DROPS
More Information on Dosage
BEPREVE family patents
34. Biktarvy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 18, 2022 |
| New Chemical Entity Exclusivity(NCE) | Feb 07, 2023 |
| M(M-82) | Feb 24, 2024 |
| Orphan Drug Exclusivity(ODE-256) | Jun 18, 2026 |
| New Indication(I-942) | Feb 23, 2027 |
| M(M-305) | Apr 24, 2027 |
| Orphan Drug Exclusivity(ODE-378) | Oct 07, 2028 |
| Orphan Drug Exclusivity(ODE-468) | Feb 23, 2031 |
NCE-1 date: 07 February, 2022
Market Authorisation Date: 07 October, 2021
Treatment: NA
Dosage: TABLET
How can I launch a generic of BIKTARVY before it's drug patent expiration?
More Information on Dosage
BIKTARVY family patents
35. Bosulif patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7919625 | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Dec, 2025
(11 months from now) | |
| US7417148 | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Dec, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2017 |
| Orphan Drug Exclusivity(ODE) | Sep 04, 2019 |
| Orphan Drug Exclusivity(ODE-30) | Sep 04, 2019 |
| New Indication(I-759) | Dec 19, 2020 |
| Orphan Drug Exclusivity(ODE-163) | Dec 19, 2024 |
| New Indication(I-923) | Sep 26, 2026 |
| New Product(NP) | Sep 26, 2026 |
| Pediatric Exclusivity(PED) | Mar 26, 2027 |
| Orphan Drug Exclusivity(ODE-444) | Sep 26, 2030 |
Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient
NCE-1 date: 26 March, 2026
Market Authorisation Date: 04 September, 2012
Treatment: A method of treating patients with accelerated, or blast phase ph+ cml with resistance or intolerance to prior therapy
Dosage: TABLET; CAPSULE
How can I launch a generic of BOSULIF before it's drug patent expiration?
More Information on Dosage
BOSULIF family patents
36. Breo Ellipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7439393 | GLAXO GRP LTD | Phenethanolamine derivatives for treatment of respiratory diseases |
May, 2025
(5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7439393 (Pediatric) | GLAXO GRP LTD | Phenethanolamine derivatives for treatment of respiratory diseases |
Nov, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 30, 2018 |
| New Indication(I-708) | Apr 30, 2018 |
| New Chemical Entity Exclusivity(NCE) | May 10, 2018 |
| M(M-202) | May 15, 2020 |
| New Patient Population(NPP) | May 13, 2026 |
| New Strength(NS) | May 13, 2026 |
| Pediatric Exclusivity(PED) | Nov 13, 2026 |
Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient
NCE-1 date: 13 November, 2025
Market Authorisation Date: 12 May, 2023
Treatment: Maintenance treatment of asthma in patients aged 5 years and older. recommended dosages: breo 100/25 or 200/25 ages 18 years and older; Breo 100/25 ages 12-17 years, and breo 50/25, ages 5-11 years
Dosage: POWDER
More Information on Dosage
BREO ELLIPTA family patents
37. Brilinta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE46276 (Pediatric) | ASTRAZENECA | Triazolo(4,5-D)pyrimidine compounds |
Apr, 2025
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2016 |
| New Indication(I-714) | Sep 03, 2018 |
| New Strength(NS) | Sep 03, 2018 |
| New Indication(I-851) | May 28, 2023 |
| New Indication(I-848) | Nov 05, 2023 |
| M(M-283) | May 09, 2025 |
| Pediatric Exclusivity(PED) | Nov 09, 2025 |
Drugs and Companies using TICAGRELOR ingredient
NCE-1 date: 09 November, 2024
Market Authorisation Date: 03 September, 2015
Treatment: NA
Dosage: TABLET
How can I launch a generic of BRILINTA before it's drug patent expiration?
More Information on Dosage
BRILINTA family patents
38. Brisdelle patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7598271 | SEBELA IRELAND LTD | Crystalline paroxetine methane sulfonate |
May, 2025
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 28, 2016 |
Drugs and Companies using PAROXETINE MESYLATE ingredient
Market Authorisation Date: 28 June, 2013
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of BRISDELLE before it's drug patent expiration?
More Information on Dosage
BRISDELLE family patents
39. Brixadi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8545832 | BRAEBURN | Lipid depot formulations |
Jun, 2025
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 23, 2026 |
Drugs and Companies using BUPRENORPHINE ingredient
Market Authorisation Date: 23 May, 2023
Treatment: A method of delivery of a bioactive agent by subcutaneous injection. a method of treatment of a human for addiction
Dosage: SOLUTION, EXTENDED RELEASE
More Information on Dosage
BRIXADI family patents
40. Bydureon patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7612176 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(3 months from now) | |
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(3 months from now) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(3 months from now) | |
| US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(6 months from now) | |
|
US8461105 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(9 months from now) | |
|
US8431685 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(9 months from now) | |
|
US7612176 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(9 months from now) | |
|
US7456254 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Dec, 2025
(1 year, 14 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2015 |
| M(M-162) | Sep 24, 2018 |
| M(M-212) | Oct 20, 2020 |
| M(M-224) | Apr 02, 2021 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: Improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adju...
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON family patents
41. Bydureon Bcise patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(3 months from now) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(3 months from now) | |
| US7612176 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(3 months from now) | |
| US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(6 months from now) | |
|
US8461105 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(9 months from now) | |
|
US8431685 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(9 months from now) | |
|
US7612176 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(9 months from now) | |
|
US7456254 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Dec, 2025
(1 year, 14 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 20, 2020 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 20 October, 2017
Treatment: Improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adju...
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON BCISE family patents
42. Bydureon Pen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(3 months from now) | |
| US7612176 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(3 months from now) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(3 months from now) | |
| US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(6 months from now) | |
|
US8461105 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(9 months from now) | |
|
US8431685 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(9 months from now) | |
|
US7612176 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(9 months from now) | |
|
US7456254 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Dec, 2025
(1 year, 14 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-224) | Apr 02, 2021 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiab...
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON PEN family patents
43. Cabenuva Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7125879 | VIIV HLTHCARE | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-184) | Jan 31, 2025 |
| New Patient Population(NPP) | Mar 29, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
CABENUVA KIT family patents
44. Children's Astepro Allergy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9919050 | BAYER HLTHCARE | Compositions comprising azelastine |
Nov, 2025
(11 months from now) | |
| US8518919 | BAYER HLTHCARE | Compositions comprising azelastine and methods of use thereof |
Nov, 2025
(11 months from now) | |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 June, 2021
Treatment: Otc use: allergy symptom reliever; Temporary relief of these symptoms due to hay fever or other upper respiratory allergies: nasal congestion, runny nose, sneezing and itchy nose
Dosage: SPRAY, METERED
How can I launch a generic of CHILDREN'S ASTEPRO ALLERGY before it's drug patent expiration?
More Information on Dosage
CHILDREN'S ASTEPRO ALLERGY family patents
45. Chlorhexidine Gluconate patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7717889 | SAGE PRODS | Disinfectant delivery system and method of providing alcohol free disinfection |
Feb, 2025
(2 months from now) | |
Drugs and Companies using CHLORHEXIDINE GLUCONATE ingredient
Market Authorisation Date: 25 April, 2005
Treatment: For the preparation of skin prior to surgery; Helps reduce bacteria that can potentially cause skin infection
Dosage: CLOTH
More Information on Dosage
CHLORHEXIDINE GLUCONATE family patents
46. Ciprodex patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8846650 | SANDOZ | Method of treating middle ear infections |
Jun, 2025
(5 months from now) | |
Drugs and Companies using CIPROFLOXACIN; DEXAMETHASONE ingredient
Market Authorisation Date: 18 July, 2003
Treatment: Treatment of acute otitis media
Dosage: SUSPENSION/DROPS
How can I launch a generic of CIPRODEX before it's drug patent expiration?
More Information on Dosage
CIPRODEX family patents
47. Combivent Respimat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7896264 | BOEHRINGER INGELHEIM | Microstructured high pressure nozzle with built-in filter function |
May, 2025
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 07, 2014 |
Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient
Market Authorisation Date: 07 October, 2011
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
COMBIVENT RESPIMAT family patents
48. Combogesic patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10532036 | AFT PHARMS US | Combination composition |
Sep, 2025
(9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 01, 2026 |
Drugs and Companies using ACETAMINOPHEN; IBUPROFEN ingredient
Market Authorisation Date: 01 March, 2023
Treatment: A method of treating mild to moderate acute pain in adults by administering 975-1000 mg of acetaminophen and 292.5-300 mg of ibuprofen in a single administration
Dosage: TABLET
More Information on Dosage
COMBOGESIC family patents
49. Complera patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7125879 | GILEAD SCIENCES INC | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8841310 | GILEAD SCIENCES INC | Combinations of a pyrimidine containing NNRTI with RT inhibitors |
Dec, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 20, 2016 |
| New Patient Population(NPP) | Dec 13, 2016 |
NCE-1 date: 21 May, 2015
Market Authorisation Date: 10 August, 2011
Treatment: Treatment of hiv infection
Dosage: TABLET
How can I launch a generic of COMPLERA before it's drug patent expiration?
More Information on Dosage
COMPLERA family patents
50. Contrave patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7375111 | NALPROPION | Compositions for affecting weight loss |
Mar, 2025
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Sep 10, 2017 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 September, 2014
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
CONTRAVE family patents
51. Coreg Cr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8101209 | WAYLIS THERAP | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
Sep, 2025
(8 months from now) | |
Drugs and Companies using CARVEDILOL PHOSPHATE ingredient
Market Authorisation Date: 20 October, 2006
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
COREG CR family patents
52. Cresemba patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6812238 | ASTELLAS | N-substituted carbamoyloxyalkyl-azolium derivatives |
Oct, 2025
(10 months from now) | |
| US10812238 | ASTELLAS | Configurable reference signals |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 06, 2020 |
| Orphan Drug Exclusivity(ODE) | Mar 06, 2022 |
| ODE*(ODE*) | Mar 06, 2022 |
| Orphan Drug Exclusivity(ODE-305) | Mar 06, 2022 |
| Orphan Drug Exclusivity(ODE-90) | Mar 06, 2022 |
| New Patient Population(NPP) | Dec 08, 2026 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 06, 2027 |
| Orphan Drug Exclusivity(ODE-453) | Dec 08, 2030 |
| Orphan Drug Exclusivity(ODE-454) | Dec 08, 2030 |
| Orphan Drug Exclusivity(ODE-458) | Dec 08, 2030 |
| Orphan Drug Exclusivity(ODE-459) | Dec 08, 2030 |
| Pediatric Exclusivity(PED) | Jun 08, 2031 |
Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient
NCE-1 date: 08 June, 2030
Market Authorisation Date: 22 November, 2022
Treatment: NA
Dosage: CAPSULE; POWDER
More Information on Dosage
CRESEMBA family patents
53. Daytrana patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9668981 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic based polymers |
Oct, 2025
(9 months from now) | |
| US9034370 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic polymers |
Oct, 2025
(9 months from now) | |
| US8632802 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic polymers |
Oct, 2025
(9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 29, 2013 |
Drugs and Companies using METHYLPHENIDATE ingredient
Market Authorisation Date: 06 April, 2006
Treatment: Method for transdermally delivering a drug to a user in need thereof
Dosage: FILM, EXTENDED RELEASE
More Information on Dosage
DAYTRANA family patents
54. Defencath patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7696182 | CORMEDIX | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
May, 2025
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2028 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 15, 2033 |
Drugs and Companies using HEPARIN SODIUM; TAUROLIDINE ingredient
NCE-1 date: 15 November, 2032
Market Authorisation Date: 15 November, 2023
Treatment: A catheter lock solution to reduce catheter-related bloodstream infections in adult patients receiving hemodialysis through a central venous catheter
Dosage: SOLUTION
More Information on Dosage
DEFENCATH family patents
55. Descovy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 28, 2020 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Indication(I-812) | Oct 03, 2022 |
| Orphan Drug Exclusivity(ODE-284) | Sep 28, 2024 |
| Orphan Drug Exclusivity(ODE-285) | Sep 28, 2024 |
| Orphan Drug Exclusivity(ODE-457) | Jan 07, 2029 |
Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient
NCE-1 date: 06 November, 2019
Market Authorisation Date: 07 January, 2022
Treatment: NA
Dosage: TABLET
More Information on Dosage
DESCOVY family patents
56. Differin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7579377 | GALDERMA LABS LP | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Feb, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Mar 17, 2013 |
| RTO(RTO) | Jul 08, 2019 |
Drugs and Companies using ADAPALENE ingredient
Market Authorisation Date: 19 June, 2007
Treatment: Topical treatment of acne vulgaris
Dosage: GEL
More Information on Dosage
DIFFERIN family patents
57. Diprivan patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8476010 (Pediatric) | FRESENIUS KABI USA | Propofol formulations with non-reactive container closures |
Jun, 2025
(5 months from now) | |
Drugs and Companies using PROPOFOL ingredient
Market Authorisation Date: 02 October, 1989
Treatment: NA
Dosage: INJECTABLE
How can I launch a generic of DIPRIVAN before it's drug patent expiration?
More Information on Dosage
DIPRIVAN family patents
58. Dojolvi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9186344 | ULTRAGENYX PHARM INC | Glycogen or polysaccharide storage disease treatment method |
Jul, 2025
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 30, 2025 |
| Orphan Drug Exclusivity(ODE-311) | Jun 30, 2027 |
Drugs and Companies using TRIHEPTANOIN ingredient
NCE-1 date: 30 June, 2024
Market Authorisation Date: 30 June, 2020
Treatment: NA
Dosage: LIQUID
More Information on Dosage
DOJOLVI family patents
59. Duaklir Pressair patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46417 | COVIS | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Feb, 2025
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Mar 29, 2022 |
Drugs and Companies using ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE ingredient
Market Authorisation Date: 29 March, 2019
Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd)
Dosage: POWDER, METERED
More Information on Dosage
DUAKLIR PRESSAIR family patents
60. Durysta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8673341 | ABBVIE | Intraocular pressure reduction with intracameral bimatoprost implants |
Feb, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 04, 2023 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 04 March, 2020
Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant
Dosage: IMPLANT
More Information on Dosage
DURYSTA family patents
61. Duvyzat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7329689 | ITALFARMACO SPA | Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester |
Jan, 2025
(30 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2029 |
| Orphan Drug Exclusivity(ODE-473) | Mar 21, 2031 |
Drugs and Companies using GIVINOSTAT HYDROCHLORIDE ingredient
NCE-1 date: 21 March, 2028
Market Authorisation Date: 21 March, 2024
Treatment: NA
Dosage: SUSPENSION
More Information on Dosage
DUVYZAT family patents
62. Duzallo patent expiration
Can you believe DUZALLO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8003681 | IRONWOOD PHARMS INC | 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester |
Aug, 2025
(8 months from now) | |
Drugs and Companies using ALLOPURINOL; LESINURAD ingredient
Market Authorisation Date: 18 August, 2017
Treatment: NA
Dosage: TABLET
More Information on Dosage
DUZALLO family patents
63. Edarbi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7157584 | AZURITY | Benzimidazole derivative and use thereof |
May, 2025
(5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7572920 | AZURITY | Benzimidazole derivative and use as a II receptor antagonist |
Jan, 2025
(22 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2016 |
Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient
NCE-1 date: 25 February, 2015
Market Authorisation Date: 25 February, 2011
Treatment: Treatment of hypertension
Dosage: TABLET
More Information on Dosage
EDARBI family patents
64. Edarbyclor patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7157584 | AZURITY | Benzimidazole derivative and use thereof |
May, 2025
(5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7572920 | AZURITY | Benzimidazole derivative and use as a II receptor antagonist |
Jan, 2025
(22 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Dec 20, 2014 |
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2016 |
Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient
NCE-1 date: 25 February, 2015
Market Authorisation Date: 20 December, 2011
Treatment: Treatment of hypertension
Dosage: TABLET
How can I launch a generic of EDARBYCLOR before it's drug patent expiration?
More Information on Dosage
EDARBYCLOR family patents
65. Edurant patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7125879 | JANSSEN PRODS | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7125879 (Pediatric) | JANSSEN PRODS | HIV inhibiting pyrimidines derivatives |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 20, 2016 |
| New Patient Population(NPP) | Aug 26, 2018 |
| M(M-223) | Feb 01, 2021 |
Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient
NCE-1 date: 21 May, 2015
Market Authorisation Date: 20 May, 2011
Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in treatment-naive adult patients with hiv-1 rna less than or equal to 100,000 at the start of therapy
Dosage: TABLET
More Information on Dosage
EDURANT family patents
66. Edurant Ped patent expiration
EDURANT PED's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7125879 | JANSSEN PRODS | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(4 months from now) | |
Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 March, 2024
Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in antiretroviral treatment-naive patients 2 years of age and older, weighing at least 14kg, with hiv-1 rna less th...
Dosage: TABLET, FOR SUSPENSION
More Information on Dosage
EDURANT PED family patents
67. Elelyso patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8790641 | PFIZER | Production of high mannose proteins in plant culture and therapeutic uses thereof |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 01, 2017 |
| New Patient Population(NPP) | Aug 27, 2017 |
Drugs and Companies using TALIGLUCERASE ALFA ingredient
NCE-1 date: 01 May, 2016
Market Authorisation Date: 01 May, 2012
Treatment: A method of catalyzing the hydrolysis of glucocerebroside to glucose and ceramide.
Dosage: POWDER
More Information on Dosage
ELELYSO family patents
68. Embeda patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8685444 | ALPHARMA PHARMS | Sequestering subunit and related compositions and methods |
Jul, 2025
(6 months from now) | |
| US8685443 | ALPHARMA PHARMS | Sequestering subunit and related compositions and methods |
Jul, 2025
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 13, 2012 |
Drugs and Companies using MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 August, 2009
Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
EMBEDA family patents
69. Entresto patent expiration
ENTRESTO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8101659 | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jan, 2025
(30 days from now) | |
|
US8101659 (Pediatric) | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jul, 2025
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 07, 2020 |
| New Patient Population(NPP) | Oct 01, 2022 |
| Pediatric Exclusivity(PED) | Apr 01, 2023 |
| M(M-82) | Feb 16, 2024 |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
NCE-1 date: 01 April, 2022
Market Authorisation Date: 07 July, 2015
Treatment: NA
Dosage: TABLET
More Information on Dosage
ENTRESTO family patents
70. Entresto Sprinkle patent expiration
ENTRESTO SPRINKLE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8101659 | NOVARTIS | Methods of treatment and pharmaceutical composition |
Jan, 2025
(30 days from now) | |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
Market Authorisation Date: 12 April, 2024
Treatment: NA
Dosage: CAPSULE, PELLETS
More Information on Dosage
ENTRESTO SPRINKLE family patents
71. Epanova patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8383678 | ASTRAZENECA | Type a gelatin capsule containing PUFA in free acid form |
Feb, 2025
(a month from now) | |
| US9012501 | ASTRAZENECA | Type A gelatin capsule containing PUFA in free acid form |
Feb, 2025
(a month from now) | |
| US9132112 | ASTRAZENECA | Type A gelatin capsule containing PUFA in free acid form |
Feb, 2025
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 05, 2019 |
Drugs and Companies using OMEGA-3-CARBOXYLIC ACIDS ingredient
NCE-1 date: 05 May, 2018
Market Authorisation Date: 05 May, 2014
Treatment: Treatment of hypertriglyceridemia
Dosage: CAPSULE
More Information on Dosage
EPANOVA family patents
72. Epiduo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7820186 | GALDERMA LABS LP | Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
Nov, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Dec 08, 2011 |
| New Patient Population(NPP) | Feb 01, 2016 |
Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient
Market Authorisation Date: 08 December, 2008
Treatment: NA
Dosage: GEL
How can I launch a generic of EPIDUO before it's drug patent expiration?
More Information on Dosage
EPIDUO family patents
73. Epipen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8048035 | MYLAN SPECIALITY LP | Automatic injector with needle cover |
Sep, 2025
(8 months from now) | |
| US7449012 | MYLAN SPECIALITY LP | Automatic injector |
Sep, 2025
(8 months from now) | |
| US7794432 | MYLAN SPECIALITY LP | Automatic injector with kickback attenuation |
Sep, 2025
(8 months from now) | |
| US8870827 | MYLAN SPECIALITY LP | Automatic injector |
Sep, 2025
(8 months from now) | |
| US9586010 | MYLAN SPECIALITY LP | Automatic injector with needle cover |
Sep, 2025
(8 months from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 03 August, 1995
Treatment: NA
Dosage: INJECTABLE
How can I launch a generic of EPIPEN before it's drug patent expiration?
More Information on Dosage
EPIPEN family patents
74. Epipen Jr. patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8048035 | MYLAN SPECIALITY LP | Automatic injector with needle cover |
Sep, 2025
(8 months from now) | |
| US9586010 | MYLAN SPECIALITY LP | Automatic injector with needle cover |
Sep, 2025
(8 months from now) | |
| US7449012 | MYLAN SPECIALITY LP | Automatic injector |
Sep, 2025
(8 months from now) | |
| US7794432 | MYLAN SPECIALITY LP | Automatic injector with kickback attenuation |
Sep, 2025
(8 months from now) | |
| US8870827 | MYLAN SPECIALITY LP | Automatic injector |
Sep, 2025
(8 months from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 03 August, 1995
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
EPIPEN JR. family patents
75. Erivedge patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9790183 | GENENTECH | Pyridyl inhibitors of hedgehog signalling |
Sep, 2025
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 30, 2017 |
Drugs and Companies using VISMODEGIB ingredient
NCE-1 date: 31 January, 2016
Market Authorisation Date: 30 January, 2012
Treatment: Method of using vismodegib to treat basal cell carcinoma
Dosage: CAPSULE
More Information on Dosage
ERIVEDGE family patents
76. Evzio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7731690 | KALEO INC | Devices, systems and methods for medicament delivery |
Jan, 2025
(30 days from now) | |
| US8016788 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2025
(3 months from now) | |
| US10335549 | KALEO INC | Devices, systems and methods for medicament delivery |
Apr, 2025
(4 months from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 April, 2014
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
EVZIO family patents
77. Evzio (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7731690 | KALEO INC | Devices, systems and methods for medicament delivery |
Jan, 2025
(30 days from now) | |
| US8016788 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2025
(3 months from now) | |
| US10335549 | KALEO INC | Devices, systems and methods for medicament delivery |
Apr, 2025
(4 months from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
EVZIO (AUTOINJECTOR) family patents
78. Exondys 51 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10781451 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months from now) | |
| US9018368 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8486907 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months from now) | |
| USRE47751 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 19, 2021 |
| Orphan Drug Exclusivity(ODE) | Sep 19, 2023 |
| Orphan Drug Exclusivity(ODE-122) | Sep 19, 2023 |
Drugs and Companies using ETEPLIRSEN ingredient
NCE-1 date: 19 September, 2020
Market Authorisation Date: 19 September, 2016
Treatment: (i)treatment of duchenne muscular dystrophy; (ii)restoring/increasing functional dystrophin protein; Or (iii) inducing skipping; Each of (i)-(iii) in patients having a confirmed mutation of the dmd ge...
Dosage: SOLUTION
More Information on Dosage
EXONDYS 51 family patents
79. Exxua patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7538116 | FABRE KRAMER | Treatment of sexual disorders |
Sep, 2025
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 22, 2028 |
Drugs and Companies using GEPIRONE HYDROCHLORIDE ingredient
NCE-1 date: 23 September, 2027
Market Authorisation Date: 22 September, 2023
Treatment: Treatment of subjects with major depression with sexual dysfunction caused by either major depression or prior treatments, or treatment of subjects with major depression without the risk of sexual dys...
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
EXXUA family patents
80. Fanapt patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9138432 | VANDA PHARMS INC | Methods for the administration of iloperidone |
Sep, 2025
(9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 06, 2014 |
| M(M-180) | May 26, 2019 |
| New Indication(I-939) | Apr 02, 2027 |
Drugs and Companies using ILOPERIDONE ingredient
NCE-1 date: 06 May, 2013
Market Authorisation Date: 06 May, 2009
Treatment: Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are being treated with fluoxetine
Dosage: TABLET
More Information on Dosage
FANAPT family patents
81. Farxiga patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(3 months from now) | |
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(3 months from now) | |
| US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(6 months from now) | |
|
US8461105 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(9 months from now) | |
|
US8431685 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(9 months from now) | |
|
US7456254 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Dec, 2025
(1 year, 14 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-157) | Mar 11, 2018 |
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-212) | Oct 20, 2020 |
| M(M-238) | Feb 22, 2022 |
| New Indication(I-841) | Oct 18, 2022 |
| New Indication(I-834) | May 05, 2023 |
| New Indication(I-857) | Apr 30, 2024 |
| M(M-298) | May 08, 2026 |
| New Patient Population(NPP) | Jun 12, 2027 |
| Pediatric Exclusivity(PED) | Dec 12, 2027 |
Drugs and Companies using DAPAGLIFLOZIN ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 08 January, 2014
Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide; Treatment of type 2 diabetes mellitus
Dosage: TABLET
How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage
FARXIGA family patents
82. Femtrace patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7572779 | APIL | Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
Oct, 2025
(9 months from now) | |
Drugs and Companies using ESTRADIOL ACETATE ingredient
Market Authorisation Date: 20 August, 2004
Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause
Dosage: TABLET
More Information on Dosage
FEMTRACE family patents
83. Fiasp Flextouch patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 29, 2020 |
| New Patient Population(NPP) | Dec 19, 2022 |
Drugs and Companies using INSULIN ASPART ingredient
Market Authorisation Date: 29 September, 2017
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
FIASP FLEXTOUCH family patents
84. Filsuvez patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8828444 | CHIESI | Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel |
Jun, 2025
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2028 |
| Orphan Drug Exclusivity(ODE-460) | Dec 18, 2030 |
Drugs and Companies using BIRCH TRITERPENES ingredient
NCE-1 date: 19 December, 2027
Market Authorisation Date: 18 December, 2023
Treatment: NA
Dosage: GEL
More Information on Dosage
FILSUVEZ family patents
85. Flovent Hfa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7500444 | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Jan, 2025
(19 days from now) | |
|
US7500444 (Pediatric) | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Jul, 2025
(6 months from now) | |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 14 May, 2004
Treatment: NA
Dosage: AEROSOL, METERED
How can I launch a generic of FLOVENT HFA before it's drug patent expiration?
More Information on Dosage
FLOVENT HFA family patents
86. Folotyn patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7622470 | ACROTECH BIOPHARMA | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin |
May, 2025
(5 months from now) | |
| US8299078 | ACROTECH BIOPHARMA | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin |
May, 2025
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 24, 2014 |
| Orphan Drug Exclusivity(ODE) | Sep 24, 2016 |
Drugs and Companies using PRALATREXATE ingredient
NCE-1 date: 24 September, 2013
Market Authorisation Date: 24 September, 2009
Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma
Dosage: SOLUTION
How can I launch a generic of FOLOTYN before it's drug patent expiration?
More Information on Dosage
FOLOTYN family patents
87. Forteo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7517334 | LILLY | Medication dispensing apparatus with spring-driven locking feature enabled by administration of final dose |
Mar, 2025
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-602) | Jul 22, 2012 |
| M(M-302) | Nov 16, 2023 |
Drugs and Companies using TERIPARATIDE ingredient
Market Authorisation Date: 25 June, 2008
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
FORTEO family patents
88. Fotivda patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6821987 | AVEO PHARMS | Quinoline derivatives and quinazoline derivatives having azolyl group |
Apr, 2025
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2026 |
Drugs and Companies using TIVOZANIB HYDROCHLORIDE ingredient
NCE-1 date: 10 March, 2025
Market Authorisation Date: 10 March, 2021
Treatment: A method of treating adults with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies by inhibiting the angiogenesis of blood vessels with a vascular end...
Dosage: CAPSULE
More Information on Dosage
FOTIVDA family patents
89. Fycompa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6949571 | CATALYST PHARMS | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
May, 2025
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 22, 2017 |
| New Indication(I-710) | Jun 19, 2018 |
Drugs and Companies using PERAMPANEL ingredient
NCE-1 date: 22 October, 2016
Market Authorisation Date: 22 October, 2012
Treatment: Treatment of epilepsy
Dosage: TABLET; SUSPENSION
More Information on Dosage
FYCOMPA family patents
90. Gattex Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9987335 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(10 months from now) | |
| US9545434 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(10 months from now) | |
| US7847061 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(10 months from now) | |
| US9572867 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(10 months from now) | |
| US9974835 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(10 months from now) | |
| US9968658 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(10 months from now) | |
| US9981014 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(10 months from now) | |
| US9545435 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(10 months from now) | |
| US9060992 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(10 months from now) | |
| US9987334 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(10 months from now) | |
| US9993528 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(10 months from now) | |
| US9592273 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(10 months from now) | |
| US9592274 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(10 months from now) | |
| US9981016 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(10 months from now) | |
| US9974837 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(10 months from now) | |
| US9539310 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(10 months from now) | |
| US9555079 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(10 months from now) | |
| US9968655 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(10 months from now) | |
| US9968656 | TAKEDA PHARMS USA | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 21, 2019 |
| Orphan Drug Exclusivity(ODE-37) | Dec 21, 2019 |
| Pediatric Exclusivity(PED) | Jun 21, 2020 |
| Orphan Drug Exclusivity(ODE-240) | May 16, 2026 |
Drugs and Companies using TEDUGLUTIDE ingredient
NCE-1 date: 22 June, 2019
Market Authorisation Date: 21 December, 2012
Treatment: Treatment of adult patients with short bowel syndrome who are dependent on parenteral support
Dosage: POWDER
More Information on Dosage
GATTEX KIT family patents
91. Genosyl patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9956373 | VERO BIOTECH INC | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(8 months from now) | |
| US11291793 | VERO BIOTECH INC | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(8 months from now) | |
| US9522249 | VERO BIOTECH INC | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(8 months from now) | |
| US8609028 | VERO BIOTECH INC | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(8 months from now) | |
| US11554241 | VERO BIOTECH INC | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(8 months from now) | |
| US8226916 | VERO BIOTECH INC | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(8 months from now) | |
| US10124142 | VERO BIOTECH INC | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(8 months from now) | |
| US8821801 | VERO BIOTECH INC | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(8 months from now) | |
| US11383059 | VERO BIOTECH INC | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(8 months from now) | |
| US10814092 | VERO BIOTECH INC | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Oct, 2025
(10 months from now) | |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 20 December, 2019
Treatment: A method of delivering nitric oxide to a patient
Dosage: GAS
More Information on Dosage
GENOSYL family patents
92. Genvoya patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 25, 2020 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Dosing Schedule(D-173) | Dec 10, 2021 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 05 November, 2015
Treatment: NA
Dosage: TABLET
More Information on Dosage
GENVOYA family patents
93. Givlaari patent expiration
GIVLAARI IPR and PTAB Proceedings
Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9150605 | ALNYLAM PHARMS INC | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Aug, 2025
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2024 |
| Orphan Drug Exclusivity(ODE-273) | Nov 20, 2026 |
Drugs and Companies using GIVOSIRAN SODIUM ingredient
NCE-1 date: 21 November, 2023
Market Authorisation Date: 20 November, 2019
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
GIVLAARI family patents
94. Glumetza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7780987 | SANTARUS INC | Controlled release dosage forms |
Mar, 2025
(3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8323692 | SANTARUS INC | Controlled release dosage forms |
Mar, 2025
(3 months from now) | |
Drugs and Companies using METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 03 June, 2005
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
GLUMETZA family patents
95. Glyxambi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7407955 (Pediatric) | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Nov, 2025
(10 months from now) | |
| US8883805 | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
Nov, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 30, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient
NCE-1 date: 01 August, 2018
Market Authorisation Date: 30 January, 2015
Treatment: NA
Dosage: TABLET
How can I launch a generic of GLYXAMBI before it's drug patent expiration?
More Information on Dosage
GLYXAMBI family patents
96. Gocovri patent expiration
Can you believe GOCOVRI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8895614 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Nov, 2025
(11 months from now) | |
| US8895617 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Nov, 2025
(11 months from now) | |
| US8895616 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Nov, 2025
(11 months from now) | |
| US8796337 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Nov, 2025
(11 months from now) | |
| US8889740 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Nov, 2025
(11 months from now) | |
| US8895618 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Nov, 2025
(11 months from now) | |
| US8895615 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Nov, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-769) | Aug 24, 2020 |
| New Product(NP) | Aug 24, 2020 |
| Orphan Drug Exclusivity(ODE) | Aug 24, 2024 |
| Orphan Drug Exclusivity(ODE-153) | Aug 24, 2024 |
Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 August, 2017
Treatment: Treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
GOCOVRI family patents
97. Horizant patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6818787 | AZURITY | Prodrugs of GABA analogs, compositions and uses thereof |
Apr, 2025
(3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8686034 | AZURITY | Crystalline form of γ-aminobutyric acid analog |
Jan, 2025
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-652) | Jun 06, 2015 |
| New Chemical Entity Exclusivity(NCE) | Apr 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Jun 06, 2019 |
| Orphan Drug Exclusivity(ODE-25) | Jun 06, 2019 |
Drugs and Companies using GABAPENTIN ENACARBIL ingredient
NCE-1 date: 07 April, 2015
Market Authorisation Date: 13 December, 2011
Treatment: Management of postherpetic neuralgia (phn) in adults
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of HORIZANT before it's drug patent expiration?
More Information on Dosage
HORIZANT family patents
98. Hysingla Er patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11844865 | PURDUE PHARMA LP | Abuse-proofed oral dosage form |
Feb, 2025
(a month from now) | |
Drugs and Companies using HYDROCODONE BITARTRATE ingredient
Market Authorisation Date: 20 November, 2014
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of HYSINGLA ER before it's drug patent expiration?
More Information on Dosage
HYSINGLA ER family patents
99. Incivek patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7820671 | VERTEX PHARMS | Peptidomimetic protease inhibitors |
Feb, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 23, 2016 |
Drugs and Companies using TELAPREVIR ingredient
NCE-1 date: 24 May, 2015
Market Authorisation Date: 23 May, 2011
Treatment: NA
Dosage: TABLET
More Information on Dosage
INCIVEK family patents
100. Incruse Ellipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7498440 | GLAXO GRP ENGLAND | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8309572 | GLAXO GRP ENGLAND | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(4 months from now) | |
| US8183257 | GLAXO GRP ENGLAND | Muscarinic acetylcholine receptor antagonists |
Jul, 2025
(7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| M(M-172) | Feb 24, 2019 |
| M(M-245) | Jun 09, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE ingredient
NCE-1 date: 18 December, 2017
Market Authorisation Date: 30 April, 2014
Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.
Dosage: POWDER
More Information on Dosage
INCRUSE ELLIPTA family patents
101. Injectafer patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7612109 | AM REGENT | Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes |
Feb, 2025
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 25, 2016 |
| New Strength(NS) | Apr 28, 2024 |
| New Patient Population(NPP) | Nov 19, 2024 |
| New Indication(I-915) | May 31, 2026 |
Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient
Market Authorisation Date: 28 April, 2021
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
INJECTAFER family patents
102. Inlyta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6534524 | PF PRISM CV | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
Apr, 2025
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6534524 (Pediatric) | PF PRISM CV | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 27, 2017 |
Drugs and Companies using AXITINIB ingredient
NCE-1 date: 28 January, 2016
Market Authorisation Date: 27 January, 2012
Treatment: NA
Dosage: TABLET
How can I launch a generic of INLYTA before it's drug patent expiration?
More Information on Dosage
INLYTA family patents
103. Intermezzo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8252809 | PURDUE PHARMA | Compositions for treating insomnia |
Feb, 2025
(2 months from now) | |
| US7682628 | PURDUE PHARMA | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
Feb, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 23, 2014 |
Drugs and Companies using ZOLPIDEM TARTRATE ingredient
Market Authorisation Date: 23 November, 2011
Treatment: Method for treating insomnia
Dosage: TABLET
How can I launch a generic of INTERMEZZO before it's drug patent expiration?
More Information on Dosage
INTERMEZZO family patents
104. Invokamet patent expiration
INVOKAMET's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-735) | May 20, 2019 |
| M(M-197) | Feb 01, 2020 |
| New Indication(I-788) | Oct 29, 2021 |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 29 March, 2017
Market Authorisation Date: 08 August, 2014
Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients
Dosage: TABLET
More Information on Dosage
INVOKAMET family patents
105. Invokamet Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-735) | May 20, 2019 |
| New Indication(I-788) | Oct 29, 2021 |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 29 March, 2017
Market Authorisation Date: 20 September, 2016
Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of INVOKAMET XR before it's drug patent expiration?
More Information on Dosage
INVOKAMET XR family patents
106. Invokana patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-733) | May 20, 2019 |
| M(M-197) | Feb 01, 2020 |
| New Indication(I-788) | Oct 29, 2021 |
| New Indication(I-809) | Sep 27, 2022 |
Drugs and Companies using CANAGLIFLOZIN ingredient
NCE-1 date: 29 March, 2017
Market Authorisation Date: 29 March, 2013
Treatment: Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients
Dosage: TABLET
More Information on Dosage
INVOKANA family patents
107. Ixempra Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7312237 (Pediatric) | R-PHARM US LLC | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
Feb, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 16, 2012 |
| Pediatric Exclusivity(PED) | Apr 18, 2015 |
| M(M-61) | Oct 18, 2014 |
Drugs and Companies using IXABEPILONE ingredient
NCE-1 date: 18 April, 2014
Market Authorisation Date: 16 October, 2007
Treatment: NA
Dosage: INJECTABLE
How can I launch a generic of IXEMPRA KIT before it's drug patent expiration?
More Information on Dosage
IXEMPRA KIT family patents
108. Izervay patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7538211 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(a month from now) | |
| US9617546 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(a month from now) | |
| US7803931 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(a month from now) | |
| US10947544 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(a month from now) | |
| US7579456 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(a month from now) | |
Drugs and Companies using AVACINCAPTAD PEGOL SODIUM ingredient
Market Authorisation Date: 04 August, 2023
Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by administerting avacincaptad pegol to the eye
Dosage: SOLUTION
More Information on Dosage
IZERVAY family patents
109. Jentadueto patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7407955 (Pediatric) | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Nov, 2025
(10 months from now) | |
| US8883805 | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
Nov, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 30, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
| M(M-146) | Jul 30, 2017 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 30 January, 2012
Treatment: NA
Dosage: TABLET
How can I launch a generic of JENTADUETO before it's drug patent expiration?
More Information on Dosage
JENTADUETO family patents
110. Jentadueto Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7407955 (Pediatric) | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Nov, 2025
(10 months from now) | |
| US8883805 | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
Nov, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 May, 2016
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of JENTADUETO XR before it's drug patent expiration?
More Information on Dosage
JENTADUETO XR family patents
111. Jevtana Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7241907 | SANOFI AVENTIS US | Acetone solvate of dimethoxy docetaxel and its process of preparation |
Dec, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2015 |
| M(M-201) | May 17, 2020 |
| M(M-209) | Sep 14, 2020 |
| Pediatric Exclusivity(PED) | Nov 17, 2020 |
| M(M-128) | Dec 18, 2023 |
Drugs and Companies using CABAZITAXEL ingredient
NCE-1 date: 18 November, 2019
Market Authorisation Date: 17 June, 2010
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of JEVTANA KIT before it's drug patent expiration?
More Information on Dosage
JEVTANA KIT family patents
112. Juluca patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7125879 | VIIV HLTHCARE | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
| New Combination(NC) | Nov 21, 2020 |
Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient
NCE-1 date: 12 August, 2017
Market Authorisation Date: 21 November, 2017
Treatment: Treatment of hiv infection
Dosage: TABLET
How can I launch a generic of JULUCA before it's drug patent expiration?
More Information on Dosage
JULUCA family patents
113. Juxtapid patent expiration
JUXTAPID IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9861622 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(2 months from now) | |
| US9433617 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(2 months from now) | |
| US10555938 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(2 months from now) | |
| US8618135 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(2 months from now) | |
| US9265758 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(2 months from now) | |
| US10016404 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(2 months from now) | |
| US9364470 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 21, 2019 |
| Orphan Drug Exclusivity(ODE-36) | Dec 21, 2019 |
Drugs and Companies using LOMITAPIDE MESYLATE ingredient
NCE-1 date: 21 December, 2016
Market Authorisation Date: 21 December, 2012
Treatment: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses; A dosing regime...
Dosage: CAPSULE
More Information on Dosage
JUXTAPID family patents
114. Kaletra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8399015 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(2 months from now) | |
|
US8691878 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(2 months from now) | |
|
US8268349 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(2 months from now) | |
|
US8309613 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Jun, 2025
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-124) | Apr 27, 2013 |
Drugs and Companies using LOPINAVIR; RITONAVIR ingredient
Market Authorisation Date: 09 November, 2007
Treatment: NA
Dosage: TABLET
More Information on Dosage
KALETRA family patents
115. Kalydeco patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8629162 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jun, 2025
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2017 |
| New Indication(I-740) | Feb 21, 2017 |
| New Indication(I-705) | Dec 30, 2017 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE-20) | Jan 31, 2019 |
| New Patient Population(NPP) | May 03, 2026 |
| Orphan Drug Exclusivity(ODE-186) | Feb 21, 2021 |
| Orphan Drug Exclusivity(ODE-187) | Dec 29, 2021 |
| Orphan Drug Exclusivity(ODE-188) | Mar 17, 2022 |
| Orphan Drug Exclusivity(ODE-190) | May 17, 2024 |
| Orphan Drug Exclusivity(ODE-189) | Jul 31, 2024 |
| Orphan Drug Exclusivity(ODE-199) | Aug 15, 2025 |
| Orphan Drug Exclusivity(ODE-236) | Apr 29, 2026 |
| Orphan Drug Exclusivity(ODE-338) | Dec 21, 2027 |
| Orphan Drug Exclusivity(ODE-435) | May 03, 2030 |
Drugs and Companies using IVACAFTOR ingredient
NCE-1 date: 01 February, 2016
Market Authorisation Date: 03 May, 2023
Treatment: Treatment of a moderate to mild clinical phenotype of cf using ivacaftor in a patient age 1 month to <4 months who has at least one cftr mutation responsive to ivacaftor based on clinical and/or in vi...
Dosage: GRANULE
More Information on Dosage
KALYDECO family patents
116. Kalydeco patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8629162 | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
Jun, 2025
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2017 |
| New Indication(I-740) | Feb 21, 2017 |
| New Indication(I-705) | Dec 30, 2017 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE-20) | Jan 31, 2019 |
| New Patient Population(NPP) | May 03, 2026 |
| Orphan Drug Exclusivity(ODE-186) | Feb 21, 2021 |
| Orphan Drug Exclusivity(ODE-187) | Dec 29, 2021 |
| Orphan Drug Exclusivity(ODE-188) | Mar 17, 2022 |
| Orphan Drug Exclusivity(ODE-190) | May 17, 2024 |
| Orphan Drug Exclusivity(ODE-189) | Jul 31, 2024 |
| Orphan Drug Exclusivity(ODE-199) | Aug 15, 2025 |
| Orphan Drug Exclusivity(ODE-236) | Apr 29, 2026 |
| Orphan Drug Exclusivity(ODE-338) | Dec 21, 2027 |
| Orphan Drug Exclusivity(ODE-435) | May 03, 2030 |
Drugs and Companies using IVACAFTOR ingredient
NCE-1 date: 01 February, 2016
Market Authorisation Date: 20 May, 2019
Treatment: Use of ivacaftor for treating cystic fibrosis in a patient with a mild to moderate cf phenotype with at least one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in ...
Dosage: TABLET
More Information on Dosage
KALYDECO family patents
117. Kazano patent expiration
Can you believe KAZANO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8288539 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Jun, 2025
(6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8173663 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Mar, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 25, 2016 |
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2018 |
| M(M-177) | Apr 05, 2019 |
| M(M-300) | Jul 27, 2026 |
Drugs and Companies using ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 25 January, 2017
Market Authorisation Date: 25 January, 2013
Treatment: Method of treating diabetes comprising administering a compound such as alogliptin
Dosage: TABLET
More Information on Dosage
KAZANO family patents
118. Klisyri patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8236799 | ALMIRALL | Biaryl compositions and methods for modulating a kinase cascade |
Dec, 2025
(1 year, 12 days from now) | |
| US8980890 | ALMIRALL | Compositions and methods of treating cell proliferation disorders |
Dec, 2025
(1 year, 12 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2025 |
| New Dosing Schedule(D-192) | Jun 07, 2027 |
Drugs and Companies using TIRBANIBULIN ingredient
NCE-1 date: 14 December, 2024
Market Authorisation Date: 14 December, 2020
Treatment: NA
Dosage: OINTMENT
More Information on Dosage
KLISYRI family patents
119. Kombiglyze Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8628799 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(6 months from now) | |
| US9339472 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2014 |
| M(M-134) | May 24, 2016 |
| M(M-175) | Apr 05, 2019 |
| M(M-198) | Feb 27, 2020 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2013
Market Authorisation Date: 05 November, 2010
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
KOMBIGLYZE XR family patents
120. Koselugo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8178693 | ASTRAZENECA | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2025
(2 months from now) | |
| US7425637 | ASTRAZENECA | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 10, 2025 |
| Orphan Drug Exclusivity(ODE-288) | Apr 10, 2027 |
Drugs and Companies using SELUMETINIB SULFATE ingredient
NCE-1 date: 10 April, 2024
Market Authorisation Date: 10 April, 2020
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
KOSELUGO family patents
121. Kuvan patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9433624 (Pediatric) | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
May, 2025
(4 months from now) | |
|
US7566714 (Pediatric) | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
May, 2025
(4 months from now) | |
|
USRE43797 (Pediatric) | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin |
May, 2025
(4 months from now) | |
|
US7612073 (Pediatric) | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
May, 2025
(4 months from now) | |
|
US8067416 (Pediatric) | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
May, 2025
(4 months from now) | |
|
US8318745 (Pediatric) | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
May, 2025
(4 months from now) | |
|
US7727987 (Pediatric) | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
May, 2025
(4 months from now) | |
|
US7947681 (Pediatric) | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
May, 2025
(4 months from now) | |
| US7566462 | BIOMARIN PHARM | Stable tablet formulation |
Nov, 2025
(10 months from now) | |
| US8003126 | BIOMARIN PHARM | Stable tablet formulation |
Nov, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 13, 2012 |
| Orphan Drug Exclusivity(ODE) | Dec 13, 2014 |
| New Patient Population(NPP) | Apr 23, 2017 |
| Pediatric Exclusivity(PED) | Oct 23, 2017 |
Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient
NCE-1 date: 23 October, 2016
Market Authorisation Date: 13 December, 2007
Treatment: NA
Dosage: TABLET; POWDER
More Information on Dosage
KUVAN family patents
122. Kybella patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8846066 | ABBVIE | Methods and related compositions for reduction of fat and skin tightening |
Feb, 2025
(a month from now) | |
| US8298556 | ABBVIE | Methods and related compositions for the non-surgical removal of fat |
Aug, 2025
(7 months from now) | |
Drugs and Companies using DEOXYCHOLIC ACID ingredient
Market Authorisation Date: 29 April, 2015
Treatment: Method for reduction of submental fat
Dosage: SOLUTION
More Information on Dosage
KYBELLA family patents
123. Kyprolis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8207297 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(3 months from now) | |
| US8207125 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(3 months from now) | |
| US7232818 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8207127 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(3 months from now) | |
| US8129346 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(3 months from now) | |
| US7491704 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(3 months from now) | |
| US8207126 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2017 |
| New Indication(I-712) | Jul 24, 2018 |
| New Indication(I-722) | Jan 21, 2019 |
| New Indication(I-723) | Jan 21, 2019 |
| Orphan Drug Exclusivity(ODE) | Jul 20, 2019 |
| Orphan Drug Exclusivity(ODE-27) | Jul 20, 2019 |
| New Dosing Schedule(D-172) | Sep 28, 2021 |
| New Indication(I-842) | Aug 20, 2023 |
Drugs and Companies using CARFILZOMIB ingredient
NCE-1 date: 20 July, 2016
Market Authorisation Date: 07 June, 2018
Treatment: Kyprolis is indicated in combination with daratumumab plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy
Dosage: POWDER
How can I launch a generic of KYPROLIS before it's drug patent expiration?
More Information on Dosage
KYPROLIS family patents
124. Lantus Solostar patent expiration
LANTUS SOLOSTAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8679069 | SANOFI AVENTIS US | Pen-type injector |
Apr, 2025
(3 months from now) | |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 27 April, 2007
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
LANTUS SOLOSTAR family patents
125. Latuda patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE45573 | SUNOVION PHARMS INC | Process for producing imide compound |
Jun, 2025
(6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE45573 (Pediatric) | SUNOVION PHARMS INC | Process for producing imide compound |
Dec, 2025
(1 year, 7 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-134) | Apr 26, 2015 |
| New Chemical Entity Exclusivity(NCE) | Oct 28, 2015 |
| New Indication(I-674) | Jun 28, 2016 |
| M(M-195) | Jan 27, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
| New Patient Population(NPP) | Mar 05, 2021 |
Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient
NCE-1 date: 28 July, 2019
Market Authorisation Date: 07 December, 2011
Treatment: NA
Dosage: TABLET
How can I launch a generic of LATUDA before it's drug patent expiration?
More Information on Dosage
LATUDA family patents
126. Lenvima patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7253286 | EISAI INC | Nitrogen-containing aromatic derivatives |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-734) | May 13, 2019 |
| New Chemical Entity Exclusivity(NCE) | Feb 13, 2020 |
| New Indication(I-787) | Aug 15, 2021 |
| Orphan Drug Exclusivity(ODE) | Feb 13, 2022 |
| Orphan Drug Exclusivity(ODE-87) | Feb 13, 2022 |
| New Indication(I-807) | Sep 17, 2022 |
| M(M-269) | Jul 21, 2024 |
| New Indication(I-868) | Aug 10, 2024 |
| M(M-272) | Dec 19, 2024 |
| Orphan Drug Exclusivity(ODE-196) | Aug 15, 2025 |
| M(M-14) | Apr 03, 2027 |
| Pediatric Exclusivity(PED) | Oct 03, 2027 |
Drugs and Companies using LENVATINIB MESYLATE ingredient
NCE-1 date: 03 October, 2026
Market Authorisation Date: 13 February, 2015
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of LENVIMA before it's drug patent expiration?
More Information on Dosage
LENVIMA family patents
127. Levemir Flextouch patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8684969 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Oct, 2025
(10 months from now) | |
Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
LEVEMIR FLEXTOUCH family patents
128. Livdelzi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7301050 | GILEAD SCIENCES INC | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
Aug, 2025
(7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 14, 2029 |
| Orphan Drug Exclusivity(ODE-486) | Aug 14, 2031 |
Drugs and Companies using SELADELPAR LYSINE ingredient
NCE-1 date: 14 August, 2028
Market Authorisation Date: 14 August, 2024
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
LIVDELZI family patents
129. Locoid patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7981877 | BAUSCH | Stabilized steroid composition and method for its preparation |
Jan, 2025
(a month from now) | |
Drugs and Companies using HYDROCORTISONE BUTYRATE ingredient
Market Authorisation Date: 18 May, 2007
Treatment: NA
Dosage: LOTION
How can I launch a generic of LOCOID before it's drug patent expiration?
More Information on Dosage
LOCOID family patents
130. Lonhala Magnair Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7931212 | SUMITOMO PHARMA AM | Fluid droplet production apparatus and method |
Nov, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 05, 2020 |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 05 December, 2017
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
LONHALA MAGNAIR KIT family patents
131. Lovaza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7732488 | WOODWARD | Pharmaceutical composition comprising low concentrations of environmental pollutants |
Jan, 2025
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-87) | Sep 16, 2012 |
Drugs and Companies using OMEGA-3-ACID ETHYL ESTERS ingredient
Market Authorisation Date: 10 November, 2004
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
LOVAZA family patents
132. Lumigan patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8309605 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 months from now) | |
| US8524777 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 months from now) | |
| US8933120 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 months from now) | |
| US8278353 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 months from now) | |
| US8586630 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 months from now) | |
| US8933127 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 months from now) | |
| US8299118 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 months from now) | |
| US9241918 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 months from now) | |
| US9155716 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 months from now) | |
| US8772338 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 months from now) | |
| US8338479 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 31, 2013 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 31 August, 2010
Treatment: Method of treating glaucoma in a patient; Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension; A method of reducing intraocular pressure in patients with open a...
Dosage: SOLUTION/DROPS
How can I launch a generic of LUMIGAN before it's drug patent expiration?
More Information on Dosage
LUMIGAN family patents
133. Lupkynis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7332472 | AURINIA | Cyclosporine analogue mixtures and their use as immunomodulating agents |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 22, 2026 |
Drugs and Companies using VOCLOSPORIN ingredient
NCE-1 date: 22 January, 2025
Market Authorisation Date: 22 January, 2021
Treatment: Treatment of patients with active lupus nephritis
Dosage: CAPSULE
More Information on Dosage
LUPKYNIS family patents
134. Lybalvi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7262298 | ALKERMES INC | 4-hydroxybenzomorphans |
Nov, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2026 |
Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient
NCE-1 date: 28 May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: NA
Dosage: TABLET
More Information on Dosage
LYBALVI family patents
135. Lymphoseek Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6409990 | CARDINAL HEALTH 414 | Macromolecular carrier for drug and diagnostic agent delivery |
May, 2025
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-687) | Jun 13, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2018 |
| Orphan Drug Exclusivity(ODE) | Jun 13, 2021 |
| Orphan Drug Exclusivity(ODE-67) | Jun 13, 2021 |
| New Patient Population(NPP) | May 19, 2024 |
Drugs and Companies using TECHNETIUM TC-99M TILMANOCEPT ingredient
NCE-1 date: 13 March, 2017
Market Authorisation Date: 13 March, 2013
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
LYMPHOSEEK KIT family patents
136. Lysteda patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7947739 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(2 months from now) | |
| US9060939 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(2 months from now) | |
| US8273795 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(2 months from now) | |
| US8487005 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(2 months from now) | |
| US8022106 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(2 months from now) | |
| US8809394 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(2 months from now) | |
| US8957113 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(2 months from now) | |
| US8791160 | AMRING PHARMS | Tranexamic acid formulations |
Mar, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Nov 13, 2012 |
Drugs and Companies using TRANEXAMIC ACID ingredient
Market Authorisation Date: 13 November, 2009
Treatment: Treatment of cyclic heavy menstrual bleeding
Dosage: TABLET
More Information on Dosage
LYSTEDA family patents
137. Mekinist patent expiration
Can you believe MEKINIST received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835443 | NOVARTIS | Pyrimidine compound and medical use thereof |
Jun, 2025
(5 months from now) | |
|
US8835443 (Pediatric) | NOVARTIS | Pyrimidine compound and medical use thereof |
Dec, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-678) | Jan 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | May 29, 2018 |
| M(M-170) | Nov 20, 2018 |
| Orphan Drug Exclusivity(ODE) | May 29, 2020 |
| Orphan Drug Exclusivity(ODE-48) | May 29, 2020 |
| New Indication(I-745) | Jun 22, 2020 |
| Orphan Drug Exclusivity(ODE-57) | Jan 08, 2021 |
| New Indication(I-778) | Apr 30, 2021 |
| New Indication(I-781) | May 04, 2021 |
| M(M-246) | Oct 06, 2022 |
| Orphan Drug Exclusivity(ODE-148) | Jun 22, 2024 |
| Orphan Drug Exclusivity(ODE-182) | Apr 30, 2025 |
| Orphan Drug Exclusivity(ODE-183) | May 04, 2025 |
| New Indication(I-895) | Jun 22, 2025 |
| Pediatric Exclusivity(PED) | Sep 16, 2026 |
| New Indication(I-908) | Mar 16, 2026 |
| New Product(NP) | Mar 16, 2026 |
| Orphan Drug Exclusivity(ODE-428) | Mar 16, 2030 |
Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient
NCE-1 date: 22 December, 2024
Market Authorisation Date: 29 May, 2013
Treatment: Mekinist is indicated, in combination with dabrafenib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic thera...
Dosage: TABLET; SOLUTION
More Information on Dosage
MEKINIST family patents
138. Mektovi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7777050 | ARRAY BIOPHARMA INC | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2023 |
| Orphan Drug Exclusivity(ODE-194) | Jun 27, 2025 |
| New Indication(I-928) | Oct 11, 2026 |
Drugs and Companies using BINIMETINIB ingredient
NCE-1 date: 27 June, 2022
Market Authorisation Date: 27 June, 2018
Treatment: NA
Dosage: TABLET
More Information on Dosage
MEKTOVI family patents
139. Mirvaso patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8231885 | GALDERMA LABS LP | Compounds, formulations, and methods for ameliorating telangiectasis |
May, 2025
(5 months from now) | |
| US8410102 | GALDERMA LABS LP | Methods and compositions for treating or preventing erythema |
May, 2025
(5 months from now) | |
| US8426410 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
May, 2025
(5 months from now) | |
| US7439241 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing rosacea |
Aug, 2025
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 23, 2016 |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 23 August, 2013
Treatment: Topical treatment of facial erythema of rosacea
Dosage: GEL
More Information on Dosage
MIRVASO family patents
140. Myfembree patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7300935 | SUMITOMO PHARMA | Thienopyrimidine compounds and use thereof |
Jan, 2025
(a month from now) | |
| US8058280 | SUMITOMO PHARMA | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
Jan, 2025
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 26, 2024 |
| New Indication(I-898) | Aug 05, 2025 |
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2025 |
| M(M-289) | Jan 27, 2026 |
Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient
NCE-1 date: 18 December, 2024
Market Authorisation Date: 26 May, 2021
Treatment: NA
Dosage: TABLET
More Information on Dosage
MYFEMBREE family patents
141. Naloxone Hydrochloride (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7731690 | KALEO INC | Devices, systems and methods for medicament delivery |
Jan, 2025
(30 days from now) | |
| US8016788 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2025
(3 months from now) | |
| US10335549 | KALEO INC | Devices, systems and methods for medicament delivery |
Apr, 2025
(4 months from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 February, 2022
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
NALOXONE HYDROCHLORIDE (AUTOINJECTOR) family patents
142. Namenda Xr patent expiration
NAMENDA XR's oppositions filed in EPO
NAMENDA XR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8168209 | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(11 months from now) | |
| US8329752 | ABBVIE | Composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(11 months from now) | |
| US8362085 | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(11 months from now) | |
| US8598233 | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(11 months from now) | |
| US8173708 | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(11 months from now) | |
| US8283379 | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jun 21, 2013 |
| M(M-138) | Jul 03, 2017 |
| Pediatric Exclusivity(PED) | Jan 03, 2018 |
Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 June, 2010
Treatment: Treatment of moderate to severe dementia of the alzheimer's type
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of NAMENDA XR before it's drug patent expiration?
More Information on Dosage
NAMENDA XR family patents
143. Namzaric patent expiration
NAMZARIC IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8283379 | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(11 months from now) | |
| US8173708 | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(11 months from now) | |
| US8580858 | ABBVIE | Compositions for the treatment of CNS-related conditions |
Nov, 2025
(11 months from now) | |
| US8338486 | ABBVIE | Methods for the treatment of CNS-related conditions |
Nov, 2025
(11 months from now) | |
| US8293794 | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(11 months from now) | |
| US8362085 | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(11 months from now) | |
| US8168209 | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(11 months from now) | |
| US8338485 | ABBVIE | Compositions for the treatment of CNS-related conditions |
Nov, 2025
(11 months from now) | |
| US8598233 | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(11 months from now) | |
| US8329752 | ABBVIE | Composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(11 months from now) | |
Drugs and Companies using DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 July, 2016
Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of NAMZARIC before it's drug patent expiration?
More Information on Dosage
NAMZARIC family patents
144. Naropin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7828787 | FRESENIUS KABI USA | Connector for packaging containing medical fluids and packaging for medical fluids |
Oct, 2025
(10 months from now) | |
Drugs and Companies using ROPIVACAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 January, 2011
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of NAROPIN before it's drug patent expiration?
More Information on Dosage
NAROPIN family patents
145. Nerlynx patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7982043 | PUMA BIOTECH | Protein tyrosine kinase enzyme inhibitors |
Oct, 2025
(9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 17, 2022 |
| New Indication(I-823) | Feb 25, 2023 |
| New Dosing Schedule(D-182) | Jun 28, 2024 |
Drugs and Companies using NERATINIB MALEATE ingredient
NCE-1 date: 17 July, 2021
Market Authorisation Date: 17 July, 2017
Treatment: Extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer, to follow adjuvant trastuzumab based therapy
Dosage: TABLET
More Information on Dosage
NERLYNX family patents
146. Nesina patent expiration
Can you believe NESINA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8288539 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Mar, 2025
(2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8173663 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Dec, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2018 |
| M(M-177) | Apr 05, 2019 |
| M(M-300) | Jul 27, 2026 |
Drugs and Companies using ALOGLIPTIN BENZOATE ingredient
NCE-1 date: 25 January, 2017
Market Authorisation Date: 25 January, 2013
Treatment: Method of treating diabetes comprising administering a compound such as alogliptin
Dosage: TABLET
More Information on Dosage
NESINA family patents
147. Neupro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8246980 | UCB INC | Transdermal delivery system |
Nov, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 09, 2012 |
| New Indication(I-646) | Apr 02, 2015 |
| New Indication(I-647) | Apr 02, 2015 |
Drugs and Companies using ROTIGOTINE ingredient
NCE-1 date: 10 May, 2011
Market Authorisation Date: 02 April, 2012
Treatment: NA
Dosage: FILM, EXTENDED RELEASE
More Information on Dosage
NEUPRO family patents
148. Nevanac patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071648 | HARROW EYE | Topical nepafenac formulations |
Dec, 2025
(11 months from now) | |
| US8324281 | HARROW EYE | Topical nepafenac formulations |
Dec, 2025
(11 months from now) | |
Drugs and Companies using NEPAFENAC ingredient
Market Authorisation Date: 19 August, 2005
Treatment: NA
Dosage: SUSPENSION/DROPS
More Information on Dosage
NEVANAC family patents
149. Nextstellis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7732430 | MAYNE PHARMA | Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception |
Mar, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 15, 2026 |
Drugs and Companies using DROSPIRENONE; ESTETROL ingredient
NCE-1 date: 15 April, 2025
Market Authorisation Date: 15 April, 2021
Treatment: Use by females of reproductive potential to prevent pregnancy
Dosage: TABLET
More Information on Dosage
NEXTSTELLIS family patents
150. Norditropin Flexpro patent expiration
NORDITROPIN FLEXPRO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8684969 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN RECOMBINANT ingredient
Market Authorisation Date: 23 January, 2015
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
NORDITROPIN FLEXPRO family patents
151. Norditropin Flexpro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8684969 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN ingredient
Market Authorisation Date: 23 January, 2015
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
NORDITROPIN FLEXPRO family patents
152. Norvir patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8691878 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(2 months from now) | |
|
US8268349 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(2 months from now) | |
|
US8399015 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-184) | Jun 07, 2024 |
Drugs and Companies using RITONAVIR ingredient
Market Authorisation Date: 10 February, 2010
Treatment: NA
Dosage: TABLET
More Information on Dosage
NORVIR family patents
153. Novolog Flextouch patent expiration
NOVOLOG FLEXTOUCH's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8684969 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Oct, 2025
(10 months from now) | |
Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
NOVOLOG FLEXTOUCH family patents
154. Nucynta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7994364 | COLLEGIUM PHARM INC | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Jun, 2025
(6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7994364 (Pediatric) | COLLEGIUM PHARM INC | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Dec, 2025
(1 year, 11 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
| New Patient Population(NPP) | Jul 03, 2026 |
| Pediatric Exclusivity(PED) | Jan 03, 2027 |
Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient
NCE-1 date: 03 January, 2026
Market Authorisation Date: 20 November, 2008
Treatment: Management of moderate to severe acute pain
Dosage: TABLET; SOLUTION
More Information on Dosage
NUCYNTA family patents
155. Nucynta Er patent expiration
NUCYNTA ER IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7994364 | COLLEGIUM PHARM INC | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Jun, 2025
(6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7994364 (Pediatric) | COLLEGIUM PHARM INC | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Dec, 2025
(1 year, 11 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
| New Dosage Form(NDF) | Aug 25, 2014 |
| New Indication(I-656) | Aug 28, 2015 |
Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient
NCE-1 date: 20 November, 2012
Market Authorisation Date: 25 August, 2011
Treatment: Management of neuropathic pain associated with diabetic peripheral neuropathy
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of NUCYNTA ER before it's drug patent expiration?
More Information on Dosage
NUCYNTA ER family patents
156. Nulibry patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7504095 | SENTYNL THERAPS INC | Method for obtaining precursor Z and use thereof for the production of a means for therapy of human molybdenum cofactor deficiency |
Jan, 2025
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-286) | Oct 27, 2025 |
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2026 |
| Orphan Drug Exclusivity(ODE-342) | Feb 26, 2028 |
Drugs and Companies using FOSDENOPTERIN HYDROBROMIDE ingredient
NCE-1 date: 26 February, 2025
Market Authorisation Date: 26 February, 2021
Treatment: Method of treating molybdenum cofactor deficiency type a
Dosage: POWDER
More Information on Dosage
NULIBRY family patents
157. Nuplazid patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7923564 | ACADIA PHARMS INC | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms |
Sep, 2025
(9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 29, 2021 |
Drugs and Companies using PIMAVANSERIN TARTRATE ingredient
NCE-1 date: 29 April, 2020
Market Authorisation Date: 28 June, 2018
Treatment: NA
Dosage: TABLET; CAPSULE
How can I launch a generic of NUPLAZID before it's drug patent expiration?
More Information on Dosage
NUPLAZID family patents
158. Nuzyra patent expiration
Can you believe NUZYRA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7553828 | PARATEK PHARMS INC | 9-aminomethyl substituted minocycline compounds |
Jun, 2025
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 02, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Oct 02, 2028 |
Drugs and Companies using OMADACYCLINE TOSYLATE ingredient
NCE-1 date: 03 October, 2027
Market Authorisation Date: 02 October, 2018
Treatment: NA
Dosage: TABLET; POWDER
More Information on Dosage
NUZYRA family patents
159. Odefsey patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(4 months from now) | |
| US7125879 | GILEAD SCIENCES INC | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-206) | Aug 21, 2020 |
| M(M-207) | Aug 21, 2020 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 01 March, 2016
Treatment: Treatment of hiv infection
Dosage: TABLET
More Information on Dosage
ODEFSEY family patents
160. Ofev patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6762180 | BOEHRINGER INGELHEIM | Substituted indolines which inhibit receptor tyrosine kinases |
Oct, 2025
(9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
| Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
| Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
| New Indication(I-805) | Sep 06, 2022 |
| New Indication(I-825) | Mar 09, 2023 |
| Orphan Drug Exclusivity(ODE-261) | Sep 06, 2026 |
| Pediatric Exclusivity(PED) | Mar 06, 2027 |
Drugs and Companies using NINTEDANIB ESYLATE ingredient
NCE-1 date: 06 March, 2026
Market Authorisation Date: 15 October, 2014
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
OFEV family patents
161. Ogsiveo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7951958 | SPRINGWORKS | Imidazole compounds for the treatment of neurodegenerative disorders |
Mar, 2025
(2 months from now) | |
| US7342118 | SPRINGWORKS | Imidazole compounds for the treatment of neurodegenerative disorders |
Aug, 2025
(8 months from now) | |
| US7795447 | SPRINGWORKS | Imidazole compounds for the treatment of neurodegenerative disorders |
Aug, 2025
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 27, 2028 |
| ODE*(ODE*) | Nov 27, 2030 |
| Orphan Drug Exclusivity(ODE-452) | Nov 27, 2030 |
Drugs and Companies using NIROGACESTAT HYDROBROMIDE ingredient
NCE-1 date: 28 November, 2027
Market Authorisation Date: 27 November, 2023
Treatment: NA
Dosage: TABLET
More Information on Dosage
OGSIVEO family patents
162. Olux E patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8962000 | NORVIUM BIOSCIENCE | Microemulsion and sub-micron emulsion process and compositions |
Aug, 2025
(8 months from now) | |
Drugs and Companies using CLOBETASOL PROPIONATE ingredient
Market Authorisation Date: 12 January, 2007
Treatment: Treatment of corticosteroid-responsive dermatoses
Dosage: AEROSOL, FOAM
How can I launch a generic of OLUX E before it's drug patent expiration?
More Information on Dosage
OLUX E family patents
163. Olysio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7671032 | JANSSEN PRODS | HCV NS-3 serine protease inhibitors |
May, 2025
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-697) | Nov 05, 2017 |
| New Dosing Schedule(D-151) | Oct 05, 2018 |
| New Indication(I-717) | Oct 05, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 22, 2018 |
| M(M-171) | Feb 26, 2019 |
| M(M-179) | May 20, 2019 |
Drugs and Companies using SIMEPREVIR SODIUM ingredient
NCE-1 date: 22 November, 2017
Market Authorisation Date: 22 November, 2013
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
OLYSIO family patents
164. Omegaven patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9566260 | FRESENIUS KABI USA | Treatment and prevention of liver disease associated with parenteral nutrition (PN) |
Jul, 2025
(6 months from now) | |
| US9629821 | FRESENIUS KABI USA | Treatment and prevention of liver disease associated with parenteral nutrition (PN) |
Jul, 2025
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2023 |
| Orphan Drug Exclusivity(ODE-202) | Jul 27, 2025 |
Drugs and Companies using FISH OIL TRIGLYCERIDES ingredient
NCE-1 date: 27 July, 2022
Market Authorisation Date: 27 July, 2018
Treatment: Treatment of liver disease through nutrition for patients under the age of 12; Use for patients with parenteral nutrition associated cholestasis or parenteral nutrition associated liver disease
Dosage: EMULSION
More Information on Dosage
OMEGAVEN family patents
165. Omeprazole patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9023391 | DEXCEL PHARMA | Stable benzimidazole formulation |
Aug, 2025
(7 months from now) | |
Drugs and Companies using OMEPRAZOLE ingredient
Market Authorisation Date: 04 December, 2007
Treatment: NA
Dosage: TABLET, DELAYED RELEASE
More Information on Dosage
OMEPRAZOLE family patents
166. Onivyde patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9782349 | IPSEN | Liposomes useful for drug delivery |
May, 2025
(4 months from now) | |
| US10722508 | IPSEN | Liposomes useful for drug delivery |
May, 2025
(4 months from now) | |
| US9724303 | IPSEN | Liposomes useful for drug delivery |
May, 2025
(4 months from now) | |
| US8992970 | IPSEN | Liposomes useful for drug delivery |
May, 2025
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9730891 | IPSEN | Liposomes useful for drug delivery |
May, 2025
(4 months from now) | |
| US8703181 | IPSEN | Liposomes useful for drug delivery |
May, 2025
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 22, 2018 |
| Orphan Drug Exclusivity(ODE) | Oct 22, 2022 |
| Orphan Drug Exclusivity(ODE-99) | Oct 22, 2022 |
| New Indication(I-932) | Feb 13, 2027 |
| Orphan Drug Exclusivity(ODE-463) | Feb 13, 2031 |
Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient
Market Authorisation Date: 22 October, 2015
Treatment: Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of pancreatic cancer
Dosage: INJECTABLE, LIPOSOMAL
More Information on Dosage
ONIVYDE family patents
167. Onpattro patent expiration
Can you believe ONPATTRO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8334373 | ALNYLAM PHARMS INC | Nuclease resistant double-stranded ribonucleic acid |
May, 2025
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
| Orphan Drug Exclusivity(ODE-197) | Aug 10, 2025 |
| M(M-270) | Jan 13, 2026 |
Drugs and Companies using PATISIRAN SODIUM ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
ONPATTRO family patents
168. Onzetra Xsail patent expiration
ONZETRA XSAIL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7975690 | CURRAX | Nasal devices |
Aug, 2025
(8 months from now) | |
| US8590530 | CURRAX | Nasal delivery devices |
Sep, 2025
(8 months from now) | |
| US9108015 | CURRAX | Nasal delivery devices |
Sep, 2025
(8 months from now) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 27 January, 2016
Treatment: Method of drug delivery via the nasal cavity
Dosage: POWDER
More Information on Dosage
ONZETRA XSAIL family patents
169. Opana Er patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8192722 | ENDO PHARMS | Abuse-proof dosage form |
Sep, 2025
(8 months from now) | |
Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 09 December, 2011
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
OPANA ER family patents
170. Opsumit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7094781 | ACTELION | Sulfamides and their use as endothelin receptor antagonists |
Dec, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 18, 2018 |
| Orphan Drug Exclusivity(ODE) | Oct 18, 2020 |
| Orphan Drug Exclusivity(ODE-54) | Oct 18, 2020 |
Drugs and Companies using MACITENTAN ingredient
NCE-1 date: 18 October, 2017
Market Authorisation Date: 18 October, 2013
Treatment: NA
Dosage: TABLET
How can I launch a generic of OPSUMIT before it's drug patent expiration?
More Information on Dosage
OPSUMIT family patents
171. Opsynvi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7094781 | ACTELION | Sulfamides and their use as endothelin receptor antagonists |
Dec, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 22, 2027 |
| Orphan Drug Exclusivity(ODE-475) | Mar 22, 2031 |
Drugs and Companies using MACITENTAN; TADALAFIL ingredient
Market Authorisation Date: 22 March, 2024
Treatment: NA
Dosage: TABLET
More Information on Dosage
OPSYNVI family patents
172. Oracea patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8206740 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Dec, 2025
(1 year, 8 days from now) | |
Drugs and Companies using DOXYCYCLINE ingredient
Market Authorisation Date: 26 May, 2006
Treatment: Treatment of only inflammatory lesions (papules and pustules) of rosacea
Dosage: CAPSULE
More Information on Dosage
ORACEA family patents
173. Oraverse patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7575757 | SEPTODONT HOLDING | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
Apr, 2025
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 18, 2019 |
Drugs and Companies using PHENTOLAMINE MESYLATE ingredient
Market Authorisation Date: 09 May, 2008
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
ORAVERSE family patents
174. Orgovyx patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8058280 | SUMITOMO PHARMA | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
Jan, 2025
(a month from now) | |
| US7300935 | SUMITOMO PHARMA | Thienopyrimidine compounds and use thereof |
Jan, 2025
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2025 |
Drugs and Companies using RELUGOLIX ingredient
NCE-1 date: 18 December, 2024
Market Authorisation Date: 18 December, 2020
Treatment: NA
Dosage: TABLET
More Information on Dosage
ORGOVYX family patents
175. Orserdu patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8399520 | STEMLINE THERAP | Selective estrogen receptor modulator |
Dec, 2025
(1 year, 9 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 27, 2028 |
Drugs and Companies using ELACESTRANT DIHYDROCHLORIDE ingredient
NCE-1 date: 27 January, 2027
Market Authorisation Date: 27 January, 2023
Treatment: Treatment of an er-positive breast cancer
Dosage: TABLET
More Information on Dosage
ORSERDU family patents
176. Oseni patent expiration
Can you believe OSENI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8288539 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Mar, 2025
(2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8173663 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Mar, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 25, 2016 |
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2018 |
| M(M-177) | Apr 05, 2019 |
Drugs and Companies using ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE ingredient
NCE-1 date: 25 January, 2017
Market Authorisation Date: 25 January, 2013
Treatment: Method of treating diabetes comprising administering a compound such as alogliptin
Dosage: TABLET
More Information on Dosage
OSENI family patents
177. Osmolex Er patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8895615 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Nov, 2025
(11 months from now) | |
| US8889740 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Nov, 2025
(11 months from now) | |
| US8895614 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Nov, 2025
(11 months from now) | |
| US8987333 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Nov, 2025
(11 months from now) | |
| US8895616 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Nov, 2025
(11 months from now) | |
| US8796337 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Nov, 2025
(11 months from now) | |
| US8895617 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Nov, 2025
(11 months from now) | |
| US9072697 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Nov, 2025
(11 months from now) | |
| US8895618 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Nov, 2025
(11 months from now) | |
| US8574626 | SUPERNUS PHARMS | Osmotic device containing amantadine and an osmotic salt |
Nov, 2025
(11 months from now) | |
Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 February, 2018
Treatment: Treatment of drug-induced extrapyramidal reactions in adult patients with parkinson's disease; Treatment of parkinson's disease; Treatment of drug-induced extrapyramidal reaction in adult patients; A ...
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
OSMOLEX ER family patents
178. Osphena patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6245819 | DUCHESNAY | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
Jul, 2025
(7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2018 |
| New Indication(I-793) | Jan 25, 2022 |
Drugs and Companies using OSPEMIFENE ingredient
NCE-1 date: 26 February, 2017
Market Authorisation Date: 26 February, 2013
Treatment: Treatment of dyspareunia associated with menopause
Dosage: TABLET
How can I launch a generic of OSPHENA before it's drug patent expiration?
More Information on Dosage
OSPHENA family patents
179. Oxaydo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7201920 | ZYLA | Methods and compositions for deterring abuse of opioid containing dosage forms |
Mar, 2025
(2 months from now) | |
Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 June, 2011
Treatment: NA
Dosage: TABLET
More Information on Dosage
OXAYDO family patents
180. Oxycontin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10696684 | PURDUE PHARMA LP | Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(3 months from now) | |
| US9522919 | PURDUE PHARMA LP | Oxycodone compositions |
Mar, 2025
(3 months from now) | |
| US10407434 | PURDUE PHARMA LP | Process for preparing oxycodone compositions |
Mar, 2025
(3 months from now) | |
| US9073933 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7674799 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(3 months from now) | |
| US7683072 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(3 months from now) | |
| US7674800 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(3 months from now) | |
| US12060361 | PURDUE PHARMA LP | Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(3 months from now) | |
| US7776314 | PURDUE PHARMA LP | Abuse-proofed dosage system |
Apr, 2025
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-153) | Apr 16, 2016 |
| New Patient Population(NPP) | Aug 13, 2018 |
Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 12 December, 1995
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
OXYCONTIN family patents
181. Ozempic patent expiration
What is Ozempic?
Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.
What is the Ozempic controversy?
The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.
OZEMPIC's oppositions filed in EPO
OZEMPIC IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8114833 | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(7 months from now) | |
| US11446443 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(10 months from now) | |
| US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Indication(I-822) | Jan 16, 2023 |
| New Dosing Schedule(D-185) | Mar 28, 2025 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 05 December, 2017
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of OZEMPIC before it's drug patent expiration?
More Information on Dosage
OZEMPIC family patents
182. Pexeva patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7598271 | SEBELA IRELAND LTD | Crystalline paroxetine methane sulfonate |
May, 2025
(4 months from now) | |
Drugs and Companies using PAROXETINE MESYLATE ingredient
Market Authorisation Date: 03 July, 2003
Treatment: NA
Dosage: TABLET
More Information on Dosage
PEXEVA family patents
183. Pomalyst patent expiration
Can you believe POMALYST received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8198262 | BRISTOL | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Jun, 2025
(6 months from now) | |
|
US8198262 (Pediatric) | BRISTOL | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Dec, 2025
(1 year, 1 day from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 08, 2018 |
| New Indication(I-707) | Apr 23, 2018 |
| Orphan Drug Exclusivity(ODE) | Feb 08, 2020 |
| Orphan Drug Exclusivity(ODE-43) | Feb 08, 2020 |
| M(M-14) | Nov 20, 2023 |
| Orphan Drug Exclusivity(ODE-296) | May 14, 2027 |
| Orphan Drug Exclusivity(ODE-297) | May 14, 2027 |
| Pediatric Exclusivity(PED) | Nov 14, 2027 |
Drugs and Companies using POMALIDOMIDE ingredient
NCE-1 date: 14 November, 2026
Market Authorisation Date: 08 February, 2013
Treatment: Use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on o...
Dosage: CAPSULE
How can I launch a generic of POMALYST before it's drug patent expiration?
More Information on Dosage
POMALYST family patents
184. Ponvory patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE43728 | VANDA PHARMS INC | Thiazolidin-4-one derivatives |
Nov, 2025
(10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8273779 | VANDA PHARMS INC | Thiazolidin 4-one derivatives |
Dec, 2025
(1 year, 1 day from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 18, 2026 |
Drugs and Companies using PONESIMOD ingredient
NCE-1 date: 18 March, 2025
Market Authorisation Date: 18 March, 2021
Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
Dosage: TABLET
More Information on Dosage
PONVORY family patents
185. Posimir patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8153661 | INNOCOLL | Controlled delivery system |
Sep, 2025
(8 months from now) | |
| US8846072 | INNOCOLL | Controlled delivery system |
Sep, 2025
(8 months from now) | |
| US8753665 | INNOCOLL | Controlled delivery system |
Sep, 2025
(8 months from now) | |
| US8153149 | INNOCOLL | Controlled delivery system |
Sep, 2025
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 01, 2024 |
Drugs and Companies using BUPIVACAINE ingredient
Market Authorisation Date: 01 February, 2021
Treatment: Method for providing sustained local anesthesia for at least 24 hours
Dosage: SOLUTION
More Information on Dosage
POSIMIR family patents
186. Pradaxa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7932273 | BOEHRINGER INGELHEIM | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
Sep, 2025
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 19, 2015 |
| New Indication(I-682) | Apr 04, 2017 |
| New Indication(I-683) | Apr 04, 2017 |
| M(M-168) | Nov 20, 2018 |
| New Strength(NS) | Nov 20, 2018 |
| New Indication(I-862) | Jun 21, 2024 |
| New Product(NP) | Jun 21, 2024 |
| Pediatric Exclusivity(PED) | Dec 21, 2024 |
Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient
Market Authorisation Date: 21 June, 2021
Treatment: NA
Dosage: PELLETS; CAPSULE
More Information on Dosage
PRADAXA family patents
187. Proair Digihaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10765820 | TEVA BRANDED PHARM | Dry powder inhalation apparatus |
May, 2025
(5 months from now) | |
| US9463288 | TEVA BRANDED PHARM | Dry powder inhalation apparatus |
May, 2025
(5 months from now) | |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 21 December, 2018
Treatment: NA
Dosage: POWDER, METERED
More Information on Dosage
PROAIR DIGIHALER family patents
188. Proair Respiclick patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10765820 | TEVA BRANDED PHARM | Dry powder inhalation apparatus |
May, 2025
(5 months from now) | |
| US9463288 | TEVA BRANDED PHARM | Dry powder inhalation apparatus |
May, 2025
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 12, 2018 |
| New Patient Population(NPP) | Apr 28, 2019 |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 21 December, 2018
Treatment: NA
Dosage: POWDER, METERED
More Information on Dosage
PROAIR RESPICLICK family patents
189. Prolensa patent expiration
PROLENSA's oppositions filed in EPO
PROLENSA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129431 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Sep, 2025
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 05, 2016 |
Drugs and Companies using BROMFENAC SODIUM ingredient
Market Authorisation Date: 05 April, 2013
Treatment: NA
Dosage: SOLUTION/DROPS
How can I launch a generic of PROLENSA before it's drug patent expiration?
More Information on Dosage
PROLENSA family patents
190. Promacta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7547719 | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jul, 2025
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
| New Indication(I-664) | Nov 16, 2015 |
| Orphan Drug Exclusivity(ODE) | Nov 20, 2015 |
| New Dosing Schedule(D-149) | Jun 11, 2018 |
| New Indication(I-711) | Jun 11, 2018 |
| Orphan Drug Exclusivity(ODE-75) | Aug 26, 2021 |
| Pediatric Exclusivity(PED) | Feb 26, 2022 |
| Orphan Drug Exclusivity(ODE-210) | Nov 16, 2025 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
NCE-1 date: 26 February, 2021
Market Authorisation Date: 20 October, 2011
Treatment: Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy
Dosage: TABLET
More Information on Dosage
PROMACTA family patents
191. Promacta Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7547719 | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jul, 2025
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-149) | Jun 11, 2018 |
| New Indication(I-711) | Jun 11, 2018 |
| Orphan Drug Exclusivity(ODE) | Aug 26, 2021 |
| Orphan Drug Exclusivity(ODE-74) | Aug 26, 2021 |
| Pediatric Exclusivity(PED) | Feb 26, 2022 |
| ODE*(ODE*) | Nov 16, 2025 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
Market Authorisation Date: 27 September, 2018
Treatment: Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy
Dosage: FOR SUSPENSION
How can I launch a generic of PROMACTA KIT before it's drug patent expiration?
More Information on Dosage
PROMACTA KIT family patents
192. Protonix patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7838027 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(3 months from now) | |
|
US7553498 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(3 months from now) | |
|
US7550153 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-614) | Nov 12, 2012 |
| M(M-54) | Nov 12, 2012 |
| Pediatric Exclusivity(PED) | May 12, 2013 |
Drugs and Companies using PANTOPRAZOLE SODIUM ingredient
Market Authorisation Date: 14 November, 2007
Treatment: NA
Dosage: FOR SUSPENSION, DELAYED RELEASE
More Information on Dosage
PROTONIX family patents
193. Qoliana patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7265117 | SANDOZ | Topical brimonidine tartrate formulations that lack chlorine dioxide |
Aug, 2025
(8 months from now) | |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 22 May, 2006
Treatment: NA
Dosage: SOLUTION/DROPS
More Information on Dosage
QOLIANA family patents
194. Qtern patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8628799 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-175) | Apr 05, 2019 |
| New Combination(NC) | Feb 27, 2020 |
| New Indication(I-804) | May 02, 2022 |
| New Strength(NS) | May 02, 2022 |
Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient
NCE-1 date: 08 January, 2018
Market Authorisation Date: 02 May, 2019
Treatment: Treatment of type 2 diabetes mellitus
Dosage: TABLET
More Information on Dosage
QTERN family patents
195. Qternmet Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8628799 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 02, 2022 |
Market Authorisation Date: 02 May, 2019
Treatment: Treatment of type 2 diabetes mellitus
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
QTERNMET XR family patents
196. Quartette patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8450299 | TEVA BRANDED PHARM | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
Oct, 2025
(9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 28, 2016 |
Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient
Market Authorisation Date: 28 March, 2013
Treatment: Prevention of pregnancy
Dosage: TABLET
More Information on Dosage
QUARTETTE family patents
197. Qutenza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10034841 | AVERITAS | Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer |
Sep, 2025
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2014 |
| Orphan Drug Exclusivity(ODE) | Nov 16, 2016 |
| New Indication(I-838) | Jul 17, 2023 |
Drugs and Companies using CAPSAICIN ingredient
NCE-1 date: 16 November, 2013
Market Authorisation Date: 16 November, 2009
Treatment: NA
Dosage: PATCH
More Information on Dosage
QUTENZA family patents
198. Renvela patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7985418 | SANOFI | Aliphatic amine polymer salts for tableting |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 12, 2012 |
| New Patient Population(NPP) | Nov 25, 2019 |
Drugs and Companies using SEVELAMER CARBONATE ingredient
Market Authorisation Date: 19 October, 2007
Treatment: NA
Dosage: TABLET
How can I launch a generic of RENVELA before it's drug patent expiration?
More Information on Dosage
RENVELA family patents
199. Rukobia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8461333 | VIIV HLTHCARE | Salts of prodrugs of piperazine and substituted piperidine antiviral agents |
Feb, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 02, 2025 |
Drugs and Companies using FOSTEMSAVIR TROMETHAMINE ingredient
NCE-1 date: 02 July, 2024
Market Authorisation Date: 02 July, 2020
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
RUKOBIA family patents
200. Ryanodex patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7758890 | EAGLE PHARMS | Treatment using dantrolene |
Jun, 2025
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 22, 2021 |
| Orphan Drug Exclusivity(ODE-69) | Jul 22, 2021 |
Drugs and Companies using DANTROLENE SODIUM ingredient
Market Authorisation Date: 22 July, 2014
Treatment: NA
Dosage: FOR SUSPENSION
More Information on Dosage
RYANODEX family patents
201. Rytelo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7494982 | GERON | Modified oligonucleotides for telomerase inhibition |
Dec, 2025
(1 year, 11 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-482) | Jun 06, 2031 |
Drugs and Companies using IMETELSTAT SODIUM ingredient
Market Authorisation Date: 06 June, 2024
Treatment: NA
Dosage: POWDER
More Information on Dosage
RYTELO family patents
202. Ryzodeg 70/30 patent expiration
RYZODEG 70/30's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 16, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
Drugs and Companies using INSULIN ASPART; INSULIN DEGLUDEC ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 25 September, 2015
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
RYZODEG 70/30 family patents
203. Sanctura Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7410978 | ALLERGAN | Once daily dosage forms of trospium |
Feb, 2025
(a month from now) | |
Drugs and Companies using TROSPIUM CHLORIDE ingredient
Market Authorisation Date: 03 August, 2007
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
SANCTURA XR family patents
204. Sancuso patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7608282 | CUMBERLAND | Transdermal granisetron |
Jan, 2025
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Sep 12, 2011 |
| NE(NE) | Sep 12, 2011 |
Drugs and Companies using GRANISETRON ingredient
Market Authorisation Date: 12 September, 2008
Treatment: Use of granisetron transdermal system to treat/prevent chemotherapy induced nausea and vomiting
Dosage: FILM, EXTENDED RELEASE
How can I launch a generic of SANCUSO before it's drug patent expiration?
More Information on Dosage
SANCUSO family patents
205. Saxenda patent expiration
SAXENDA's oppositions filed in EPO
SAXENDA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8114833 | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(7 months from now) | |
| US11446443 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(10 months from now) | |
| US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
| New Product(NP) | Jan 25, 2017 |
| New Patient Population(NPP) | Dec 04, 2023 |
Drugs and Companies using LIRAGLUTIDE ingredient
NCE-1 date: 25 January, 2014
Market Authorisation Date: 23 December, 2014
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of SAXENDA before it's drug patent expiration?
More Information on Dosage
SAXENDA family patents
206. Scenesse patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10076555 | CLIVUNEL INC | Methods of inducing melanogenesis in a subject |
Feb, 2025
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 08, 2024 |
| Orphan Drug Exclusivity(ODE-270) | Oct 08, 2026 |
Drugs and Companies using AFAMELANOTIDE ingredient
NCE-1 date: 09 October, 2023
Market Authorisation Date: 08 October, 2019
Treatment: Increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp)
Dosage: IMPLANT
More Information on Dosage
SCENESSE family patents
207. Signifor patent expiration
Can you believe SIGNIFOR received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8299209 | RECORDATI RARE | Pharmaceutical composition comprising cyclic somatostatin analogues |
Dec, 2025
(1 year, 11 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 14, 2019 |
| Orphan Drug Exclusivity(ODE-34) | Dec 14, 2019 |
Drugs and Companies using PASIREOTIDE DIASPARTATE ingredient
NCE-1 date: 14 December, 2016
Market Authorisation Date: 14 December, 2012
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
SIGNIFOR family patents
208. Soliqua 100/33 patent expiration
SOLIQUA 100/33 IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8679069 | SANOFI-AVENTIS US | Pen-type injector |
Apr, 2025
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 21 November, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
SOLIQUA 100/33 family patents
209. Solodyn patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8722650 | BAUSCH | Extended-release minocycline dosage forms |
Jun, 2025
(6 months from now) | |
| US8252776 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(6 months from now) | |
| US8268804 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(6 months from now) | |
| US7790705 | BAUSCH | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(6 months from now) | |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 08 May, 2006
Treatment: Treatment of acne
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of SOLODYN before it's drug patent expiration?
More Information on Dosage
SOLODYN family patents
210. Spinraza patent expiration
Can you believe SPINRAZA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10266822 | BIOGEN IDEC | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Dec, 2025
(11 months from now) | |
| US8110560 | BIOGEN IDEC | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Dec, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-226) | May 14, 2021 |
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 23, 2023 |
| Orphan Drug Exclusivity(ODE-127) | Dec 23, 2023 |
Drugs and Companies using NUSINERSEN SODIUM ingredient
NCE-1 date: 23 December, 2020
Market Authorisation Date: 23 December, 2016
Treatment: Treatment of spinal muscular atrophy; Treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna
Dosage: SOLUTION
More Information on Dosage
SPINRAZA family patents
211. Spiriva Respimat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7284474 (Pediatric) | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Feb, 2025
(2 months from now) | |
| US7896264 | BOEHRINGER INGELHEIM | Microstructured high pressure nozzle with built-in filter function |
May, 2025
(5 months from now) | |
|
US7896264 (Pediatric) | BOEHRINGER INGELHEIM | Microstructured high pressure nozzle with built-in filter function |
Nov, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 15, 2018 |
| New Patient Population(NPP) | Feb 15, 2020 |
| Pediatric Exclusivity(PED) | Aug 15, 2020 |
Drugs and Companies using TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 15 September, 2015
Treatment: NA
Dosage: SPRAY, METERED
How can I launch a generic of SPIRIVA RESPIMAT before it's drug patent expiration?
More Information on Dosage
SPIRIVA RESPIMAT family patents
212. Sprycel patent expiration
SPRYCEL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8680103 | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Feb, 2025
(a month from now) | |
|
US8680103 (Pediatric) | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Aug, 2025
(7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-120) | May 21, 2012 |
| Orphan Drug Exclusivity(ODE) | Jun 28, 2013 |
| M(M-94) | Oct 28, 2013 |
| New Patient Population(NPP) | Nov 09, 2020 |
| New Indication(I-791) | Dec 21, 2021 |
| Orphan Drug Exclusivity(ODE-164) | Nov 09, 2024 |
| Orphan Drug Exclusivity(ODE-225) | Dec 21, 2025 |
| Pediatric Exclusivity(PED) | Jun 21, 2026 |
Drugs and Companies using DASATINIB ingredient
Market Authorisation Date: 28 June, 2006
Treatment: NA
Dosage: TABLET
More Information on Dosage
SPRYCEL family patents
213. Spy Agent Green Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9421280 | NOVADAQ TECH | Real time imaging during solid organ transplant |
Nov, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 21, 2021 |
| New Indication(I-911) | Jun 05, 2026 |
Drugs and Companies using INDOCYANINE GREEN ingredient
Market Authorisation Date: 21 November, 2018
Treatment: Visualization of extrahepatic biliary duct attached to donor organ in patients 12 years and older
Dosage: POWDER
More Information on Dosage
SPY AGENT GREEN KIT family patents
214. Stendra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6656935 | METUCHEN PHARMS | Aromatic nitrogen-containing 6-membered cyclic compounds |
Apr, 2025
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 27, 2017 |
| New Dosing Schedule(D-140) | Sep 17, 2017 |
| M(M-282) | Oct 18, 2025 |
Drugs and Companies using AVANAFIL ingredient
NCE-1 date: 27 April, 2016
Market Authorisation Date: 27 April, 2012
Treatment: Treatment of erectile dysfunction
Dosage: TABLET
How can I launch a generic of STENDRA before it's drug patent expiration?
More Information on Dosage
STENDRA family patents
215. Stiolto Respimat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7220742 | BOEHRINGER INGELHEIM | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
May, 2025
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7284474 (Pediatric) | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Feb, 2025
(2 months from now) | |
| US8034809 | BOEHRINGER INGELHEIM | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
May, 2025
(4 months from now) | |
| US7896264 | BOEHRINGER INGELHEIM | Microstructured high pressure nozzle with built-in filter function |
May, 2025
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | May 21, 2018 |
| M(M-173) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2019 |
| M(M-233) | Oct 05, 2021 |
Drugs and Companies using OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE ingredient
NCE-1 date: 31 July, 2018
Market Authorisation Date: 21 May, 2015
Treatment: Treatment of copd; Treatment of respiratory complaints
Dosage: SPRAY, METERED
More Information on Dosage
STIOLTO RESPIMAT family patents
216. Striverdi Respimat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7220742 | BOEHRINGER INGELHEIM | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
May, 2025
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8034809 | BOEHRINGER INGELHEIM | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
May, 2025
(4 months from now) | |
| US7896264 | BOEHRINGER INGELHEIM | Microstructured high pressure nozzle with built-in filter function |
May, 2025
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2019 |
Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2018
Market Authorisation Date: 31 July, 2014
Treatment: Treatment of chronic obstructive pulmonary disease (copd), chronic bronchitis or emphysema
Dosage: SPRAY, METERED
More Information on Dosage
STRIVERDI RESPIMAT family patents
217. Sumavel Dosepro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8241243 | ENDO OPERATIONS | Needleless injector drug capsule and a method for filling thereof |
Dec, 2025
(1 year, 9 days from now) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 26 November, 2013
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
SUMAVEL DOSEPRO family patents
218. Symbicort patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8875699 (Pediatric) | ASTRAZENECA | Inhaler cap strap |
May, 2025
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-582) | Feb 27, 2012 |
| New Patient Population(NPP) | Jan 27, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
| M(M-210) | Sep 11, 2020 |
| M(M-214) | Dec 20, 2020 |
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE ingredient
Market Authorisation Date: 21 July, 2006
Treatment: NA
Dosage: AEROSOL, METERED
How can I launch a generic of SYMBICORT before it's drug patent expiration?
More Information on Dosage
SYMBICORT family patents
219. Symdeko (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8629162 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jun, 2025
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 21, 2022 |
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2023 |
| Orphan Drug Exclusivity(ODE-173) | Feb 12, 2025 |
| Orphan Drug Exclusivity(ODE-247) | Jun 21, 2026 |
| Orphan Drug Exclusivity(ODE-335) | Dec 21, 2027 |
Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient
NCE-1 date: 12 February, 2022
Market Authorisation Date: 21 June, 2019
Treatment: Tezacaftor and ivacaftor for the treatment of patients with a mild to moderate clinical phenotype of cystic fibrosis having at least one cftr gene mutation that is responsive to tezacaftor/ivacaftor b...
Dosage: TABLET
More Information on Dosage
SYMDEKO (COPACKAGED) family patents
220. Symtuza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7390791 | JANSSEN PRODS | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Combination(NC) | Jul 17, 2021 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 17 July, 2018
Treatment: NA
Dosage: TABLET
More Information on Dosage
SYMTUZA family patents
221. Tafinlar patent expiration
Can you believe TAFINLAR received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835443 | NOVARTIS | Pyrimidine compound and medical use thereof |
Jun, 2025
(5 months from now) | |
|
US8835443 (Pediatric) | NOVARTIS | Pyrimidine compound and medical use thereof |
Dec, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-678) | Jan 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | May 29, 2018 |
| M(M-170) | Nov 20, 2018 |
| Orphan Drug Exclusivity(ODE) | May 29, 2020 |
| Orphan Drug Exclusivity(ODE-47) | May 29, 2020 |
| New Indication(I-745) | Jun 22, 2020 |
| Orphan Drug Exclusivity(ODE-58) | Jan 09, 2021 |
| New Indication(I-778) | Apr 30, 2021 |
| New Indication(I-781) | May 04, 2021 |
| M(M-246) | Oct 06, 2022 |
| Orphan Drug Exclusivity(ODE-147) | Jun 22, 2024 |
| Orphan Drug Exclusivity(ODE-182) | Apr 30, 2025 |
| Orphan Drug Exclusivity(ODE-183) | May 04, 2025 |
| New Indication(I-894) | Jun 22, 2025 |
| Pediatric Exclusivity(PED) | Sep 16, 2026 |
| New Indication(I-908) | Mar 16, 2026 |
| New Product(NP) | Mar 16, 2026 |
| Orphan Drug Exclusivity(ODE-428) | Mar 16, 2030 |
Drugs and Companies using DABRAFENIB MESYLATE ingredient
Market Authorisation Date: 16 March, 2023
Treatment: Tafinlar is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of ...
Dosage: TABLET, FOR SUSPENSION; CAPSULE
More Information on Dosage
TAFINLAR family patents
222. Targiniq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7674800 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(3 months from now) | |
| US9522919 | PURDUE PHARMA LP | Oxycodone compositions |
Mar, 2025
(3 months from now) | |
| US7683072 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(3 months from now) | |
| US9073933 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7674799 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jul 23, 2017 |
Drugs and Companies using NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 July, 2014
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
TARGINIQ family patents
223. Technivie patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8268349 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(2 months from now) | |
|
US8399015 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-743) | Jul 24, 2018 |
| New Product(NP) | Jul 24, 2018 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 24 July, 2015
Treatment: NA
Dosage: TABLET
More Information on Dosage
TECHNIVIE family patents
224. Tegsedi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8101743 | AKCEA THERAPS | Modulation of transthyretin expression |
Apr, 2025
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2023 |
| Orphan Drug Exclusivity(ODE-212) | Oct 05, 2025 |
Drugs and Companies using INOTERSEN SODIUM ingredient
NCE-1 date: 05 October, 2022
Market Authorisation Date: 05 October, 2018
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
TEGSEDI family patents
225. Testim patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7320968 | ENDO OPERATIONS | Pharmaceutical composition |
Jan, 2025
(a month from now) | |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 31 October, 2002
Treatment: Method for administration of testosterone
Dosage: GEL
More Information on Dosage
TESTIM family patents
226. Tobi Podhaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8664187 | MYLAN SPECIALITY LP | Methods of treatment of endobronchial infections |
Jun, 2025
(6 months from now) | |
| US7559325 | MYLAN SPECIALITY LP | Aerosolization apparatus with air inlet shield |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 22, 2016 |
Drugs and Companies using TOBRAMYCIN ingredient
Market Authorisation Date: 22 March, 2013
Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa
Dosage: POWDER
More Information on Dosage
TOBI PODHALER family patents
227. Toujeo Max Solostar patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8679069 | SANOFI US SERVICES | Pen-type injector |
Apr, 2025
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Nov 26, 2022 |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 25 February, 2015
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
TOUJEO MAX SOLOSTAR family patents
228. Toujeo Solostar patent expiration
TOUJEO SOLOSTAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8679069 | SANOFI US SERVICES | Pen-type injector |
Apr, 2025
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 25, 2018 |
| New Patient Population(NPP) | Nov 26, 2022 |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 25 February, 2015
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
TOUJEO SOLOSTAR family patents
229. Tradjenta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7407955 (Pediatric) | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Nov, 2025
(10 months from now) | |
| US8883805 | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
Nov, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-118) | Aug 13, 2015 |
| M(M-121) | Aug 13, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 02 May, 2011
Treatment: NA
Dosage: TABLET
How can I launch a generic of TRADJENTA before it's drug patent expiration?
More Information on Dosage
TRADJENTA family patents
230. Trelegy Ellipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7498440 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(4 months from now) | |
| US7439393 | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
May, 2025
(5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8309572 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(4 months from now) | |
| US8183257 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Jul, 2025
(7 months from now) | |
|
US7439393 (Pediatric) | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
Nov, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| New Indication(I-775) | Apr 24, 2021 |
| New Indication(I-843) | Sep 09, 2023 |
| New Strength(NS) | Sep 09, 2023 |
NCE-1 date: 18 December, 2017
Market Authorisation Date: 18 September, 2017
Treatment: Method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via top...
Dosage: POWDER
More Information on Dosage
TRELEGY ELLIPTA family patents
231. Tresiba patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 16, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
Drugs and Companies using INSULIN DEGLUDEC ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 21 November, 2018
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
TRESIBA family patents
232. Treximet patent expiration
TREXIMET IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7332183 | CURRAX | Multilayer dosage forms containing NSAIDs and triptans |
Oct, 2025
(9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 14, 2018 |
| Pediatric Exclusivity(PED) | Nov 14, 2018 |
Drugs and Companies using NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 14 May, 2015
Treatment: Treatment of migraine
Dosage: TABLET
More Information on Dosage
TREXIMET family patents
233. Tri-luma patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7939516 | GALDERMA LABS LP | Topical skin care composition |
May, 2025
(4 months from now) | |
Drugs and Companies using FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN ingredient
Market Authorisation Date: 18 January, 2002
Treatment: NA
Dosage: CREAM
More Information on Dosage
TRI-LUMA family patents
234. Trijardy Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7407955 (Pediatric) | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Nov, 2025
(10 months from now) | |
| US8883805 | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
Nov, 2025
(11 months from now) | |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 January, 2020
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of TRIJARDY XR before it's drug patent expiration?
More Information on Dosage
TRIJARDY XR family patents
235. Trikafta (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8629162 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jun, 2025
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 08, 2024 |
| New Chemical Entity Exclusivity(NCE) | Oct 21, 2024 |
| New Product(NP) | Apr 26, 2026 |
| Orphan Drug Exclusivity(ODE-275) | Oct 21, 2026 |
| Orphan Drug Exclusivity(ODE-323) | Dec 21, 2027 |
| Orphan Drug Exclusivity(ODE-357) | Jun 08, 2028 |
| Orphan Drug Exclusivity(ODE-433) | Apr 26, 2030 |
Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient
NCE-1 date: 22 October, 2023
Market Authorisation Date: 08 June, 2021
Treatment: Treatment of a moderate to mild clinical phenotype of cf in patients aged 2 to <6 years who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based ...
Dosage: TABLET; GRANULES
More Information on Dosage
TRIKAFTA (COPACKAGED) family patents
236. Trilipix patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7259186 | ABBVIE | Salts of fenofibric acid and pharmaceutical formulations thereof |
Jan, 2025
(22 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 15, 2011 |
Drugs and Companies using CHOLINE FENOFIBRATE ingredient
Market Authorisation Date: 15 December, 2008
Treatment: NA
Dosage: CAPSULE, DELAYED RELEASE
More Information on Dosage
TRILIPIX family patents
237. Troxyca Er patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8685443 | PFIZER | Sequestering subunit and related compositions and methods |
Jul, 2025
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 19, 2019 |
Drugs and Companies using NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 August, 2016
Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
TROXYCA ER family patents
238. Truqap patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9006430 | ASTRAZENECA | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein |
Oct, 2025
(10 months from now) | |
| US8809336 | ASTRAZENECA | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2028 |
Drugs and Companies using CAPIVASERTIB ingredient
NCE-1 date: 17 November, 2027
Market Authorisation Date: 16 November, 2023
Treatment: Treatment with fulvestrant of hr-pos. her2-neg. locally advanced or metastatic breast cancer with pik3ca/akt1/pten-alteration(s) following progression on endocrine therapy in the metastatic setting or...
Dosage: TABLET
More Information on Dosage
TRUQAP family patents
239. Tudorza Pressair patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46417 | COVIS | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Feb, 2025
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2017 |
| M(M-256) | Mar 29, 2022 |
Drugs and Companies using ACLIDINIUM BROMIDE ingredient
NCE-1 date: 23 July, 2016
Market Authorisation Date: 23 July, 2012
Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd)
Dosage: POWDER, METERED
More Information on Dosage
TUDORZA PRESSAIR family patents
240. Twinject 0.15 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7297136 | IMPAX | Medicine injection devices and methods |
Jan, 2025
(a month from now) | |
| US7621891 | IMPAX | Method and apparatus for delivering epinephrine |
Feb, 2025
(a month from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 25 November, 2009
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
TWINJECT 0.15 family patents
241. Twinject 0.3 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7297136 | IMPAX | Medicine injection devices and methods |
Jan, 2025
(a month from now) | |
| US7621891 | IMPAX | Method and apparatus for delivering epinephrine |
Feb, 2025
(a month from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 25 November, 2009
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
TWINJECT 0.3 family patents
242. Tyvaso Dpi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10130685 | UNITED THERAP | Diketopiperazine salts for drug delivery and related methods |
Aug, 2025
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 23, 2025 |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 23 May, 2022
Treatment: NA
Dosage: POWDER
More Information on Dosage
TYVASO DPI family patents
243. Utibron patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6878721 | NOVARTIS | Beta2-adrenoceptor agonists |
Feb, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
| New Product(NP) | Oct 29, 2018 |
Drugs and Companies using GLYCOPYRROLATE; INDACATEROL MALEATE ingredient
NCE-1 date: 02 July, 2015
Market Authorisation Date: 29 October, 2015
Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)
Dosage: POWDER
More Information on Dosage
UTIBRON family patents
244. Uzedy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9925268 | TEVA | Drug-containing implants and methods of use thereof |
Jan, 2025
(27 days from now) | |
| US9439905 | TEVA | Risperidone-containing implants and methods of use thereof |
Jan, 2025
(27 days from now) | |
| US10736965 | TEVA | Risperidone biodegradable implant |
Jan, 2025
(27 days from now) | |
| US9717799 | TEVA | Drug-containing implants and methods of use thereof |
Jan, 2025
(27 days from now) | |
| US9895447 | TEVA | Drug-containing PLA implants and methods of use thereof |
Jan, 2025
(27 days from now) | |
| US8802127 | TEVA | Risperidone-containing PLA:PGA implants and methods of use thereof |
Jan, 2025
(27 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 28, 2026 |
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 28 April, 2023
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
UZEDY family patents
245. Valtoco patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10265402 | NEURELIS INC | Absorption enhancers for drug administration |
May, 2025
(4 months from now) | |
| US9642913 | NEURELIS INC | Pharmaceutical composition including alkyl glycoside and an anti-seizure agent |
May, 2025
(4 months from now) | |
| US8927497 | NEURELIS INC | Absorption enhancers for intranasal administration |
Jul, 2025
(7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 10, 2023 |
| Orphan Drug Exclusivity(ODE-279) | Jan 10, 2027 |
Drugs and Companies using DIAZEPAM ingredient
Market Authorisation Date: 10 January, 2020
Treatment: Nasal administration of diazepam for treatment of intermittent, stereotypic episodes of frequent seizure activity in patients 6 years of age and older
Dosage: SPRAY
More Information on Dosage
VALTOCO family patents
246. Veltassa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7556799 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Feb, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 21, 2020 |
| New Patient Population(NPP) | Oct 02, 2026 |
| New Strength(NS) | Oct 02, 2026 |
Drugs and Companies using PATIROMER SORBITEX CALCIUM ingredient
NCE-1 date: 22 October, 2019
Market Authorisation Date: 02 October, 2023
Treatment: Treatment of hyperkalemia
Dosage: POWDER
How can I launch a generic of VELTASSA before it's drug patent expiration?
More Information on Dosage
VELTASSA family patents
247. Veltin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9492384 | ALMIRALL | Microemulsion and sub-micron emulsion process and compositions |
Aug, 2025
(8 months from now) | |
Drugs and Companies using CLINDAMYCIN PHOSPHATE; TRETINOIN ingredient
Market Authorisation Date: 16 July, 2010
Treatment: Treatment of atopic dermatitis
Dosage: GEL
More Information on Dosage
VELTIN family patents
248. Vemlidy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 11, 2019 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| M(M-255) | Feb 04, 2023 |
| M(M-266) | Aug 22, 2023 |
| New Patient Population(NPP) | Oct 17, 2025 |
Drugs and Companies using TENOFOVIR ALAFENAMIDE FUMARATE ingredient
NCE-1 date: 06 November, 2019
Market Authorisation Date: 10 November, 2016
Treatment: NA
Dosage: TABLET
More Information on Dosage
VEMLIDY family patents
249. Ventolin Hfa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7500444 | GLAXOSMITHKLINE | Actuation indicator for a dispensing device |
Jan, 2025
(19 days from now) | |
|
US7500444 (Pediatric) | GLAXOSMITHKLINE | Actuation indicator for a dispensing device |
Jul, 2025
(6 months from now) | |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 19 April, 2001
Treatment: NA
Dosage: AEROSOL, METERED
More Information on Dosage
VENTOLIN HFA family patents
250. Veramyst patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8147461 | GLAXOSMITHKLINE | Fluid dispensing device |
Mar, 2025
(2 months from now) | |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 27 April, 2007
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
VERAMYST family patents
251. Verdeso patent expiration
VERDESO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9492384 | ALMIRALL | Microemulsion and sub-micron emulsion process and compositions |
Aug, 2025
(8 months from now) | |
| US8962000 | ALMIRALL | Microemulsion and sub-micron emulsion process and compositions |
Aug, 2025
(8 months from now) | |
Drugs and Companies using DESONIDE ingredient
Market Authorisation Date: 19 September, 2006
Treatment: Treatment of atopic dermatitis
Dosage: AEROSOL, FOAM
More Information on Dosage
VERDESO family patents
252. Veregen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9770406 | ANI PHARMS | Medicament for the treatment of viral skin and tumour diseases |
Jul, 2025
(6 months from now) | |
Drugs and Companies using SINECATECHINS ingredient
Market Authorisation Date: 31 October, 2006
Treatment: Treatment of genital warts
Dosage: OINTMENT
More Information on Dosage
VEREGEN family patents
253. Viberzi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10213415 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(2 months from now) | |
| US7786158 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(2 months from now) | |
| US8609709 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9205076 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(2 months from now) | |
| US8344011 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(2 months from now) | |
| US8772325 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(2 months from now) | |
| US9700542 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2020 |
Drugs and Companies using ELUXADOLINE ingredient
NCE-1 date: 28 May, 2019
Market Authorisation Date: 27 May, 2015
Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline).; Treatment of pain associated with irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline)
Dosage: TABLET
More Information on Dosage
VIBERZI family patents
254. Victoza patent expiration
VICTOZA's oppositions filed in EPO
VICTOZA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8114833 | NOVO NORDISK INC | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
| M(M-115) | Apr 06, 2015 |
| M(M-176) | Apr 22, 2019 |
| New Indication(I-750) | Aug 25, 2020 |
| New Patient Population(NPP) | Jun 17, 2022 |
| Pediatric Exclusivity(PED) | Dec 17, 2022 |
Drugs and Companies using LIRAGLUTIDE ingredient
NCE-1 date: 17 December, 2021
Market Authorisation Date: 25 January, 2010
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of VICTOZA before it's drug patent expiration?
More Information on Dosage
VICTOZA family patents
255. Vizamyl patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7270800 | GE HEALTHCARE | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
Sep, 2025
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 25, 2018 |
Drugs and Companies using FLUTEMETAMOL F-18 ingredient
NCE-1 date: 25 October, 2017
Market Authorisation Date: 25 October, 2013
Treatment: Diagnostic radioimaging
Dosage: INJECTABLE
More Information on Dosage
VIZAMYL family patents
256. Vizimpro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8623883 | PFIZER | 4-phenylamino-quinazolin-6-yl-amides |
May, 2025
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 27, 2023 |
| Orphan Drug Exclusivity(ODE-206) | Sep 27, 2025 |
| Orphan Drug Exclusivity(ODE-213) | Sep 27, 2025 |
Drugs and Companies using DACOMITINIB ingredient
NCE-1 date: 27 September, 2022
Market Authorisation Date: 27 September, 2018
Treatment: First-line treatment of metastatic non small-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test
Dosage: TABLET
More Information on Dosage
VIZIMPRO family patents
257. Vyleesi (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6794489 | COSETTE | Compositions and methods for treatment of sexual dysfunction |
Jun, 2025
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 21, 2024 |
Drugs and Companies using BREMELANOTIDE ACETATE ingredient
NCE-1 date: 22 June, 2023
Market Authorisation Date: 21 June, 2019
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
VYLEESI (AUTOINJECTOR) family patents
258. Vyndamax patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7214695 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Dec, 2025
(1 year, 3 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214696 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Dec, 2025
(1 year, 3 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 03, 2024 |
| Orphan Drug Exclusivity(ODE-237) | May 03, 2026 |
Drugs and Companies using TAFAMIDIS ingredient
NCE-1 date: 04 May, 2023
Market Authorisation Date: 03 May, 2019
Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)
Dosage: CAPSULE
How can I launch a generic of VYNDAMAX before it's drug patent expiration?
More Information on Dosage
VYNDAMAX family patents
259. Vyndaqel patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7214695 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Dec, 2025
(1 year, 3 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214696 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Dec, 2025
(1 year, 3 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 03, 2024 |
| Orphan Drug Exclusivity(ODE-237) | May 03, 2026 |
Drugs and Companies using TAFAMIDIS MEGLUMINE ingredient
NCE-1 date: 04 May, 2023
Market Authorisation Date: 03 May, 2019
Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)
Dosage: CAPSULE
More Information on Dosage
VYNDAQEL family patents
260. Vyondys 53 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9994851 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months from now) | |
| US10968450 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months from now) | |
| US10421966 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months from now) | |
| US9024007 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months from now) | |
| US10227590 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10266827 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months from now) | |
| US10995337 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 12, 2024 |
| Orphan Drug Exclusivity(ODE-280) | Dec 12, 2026 |
Drugs and Companies using GOLODIRSEN ingredient
NCE-1 date: 13 December, 2023
Market Authorisation Date: 12 December, 2019
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients having a confirmed mutation of the dmd gene that is amenable to exon 53 skipping
Dosage: SOLUTION
More Information on Dosage
VYONDYS 53 family patents
261. Vyxeos patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8431806 | CELATOR PHARMS | Liposomal formulations of anthracycline agents and cytidine analogs |
Apr, 2025
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 03, 2020 |
| New Patient Population(NPP) | Mar 30, 2024 |
| Orphan Drug Exclusivity(ODE-287) | Aug 03, 2024 |
| Orphan Drug Exclusivity(ODE-350) | Mar 30, 2028 |
Drugs and Companies using CYTARABINE; DAUNORUBICIN ingredient
Market Authorisation Date: 03 August, 2017
Treatment: For the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in adults and pediatric patients 1 year and older
Dosage: POWDER
More Information on Dosage
VYXEOS family patents
262. Vyzulta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7910767 | BAUSCH AND LOMB | Prostaglandin derivatives |
Jan, 2025
(20 days from now) | |
| US7273946 | BAUSCH AND LOMB | Prostaglandin derivatives |
Oct, 2025
(9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7629345 | BAUSCH AND LOMB | Prostaglandin derivatives |
Jan, 2025
(20 days from now) | |
Drugs and Companies using LATANOPROSTENE BUNOD ingredient
Market Authorisation Date: 02 November, 2017
Treatment: Reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension
Dosage: SOLUTION/DROPS
More Information on Dosage
VYZULTA family patents
263. Wainua (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8101743 | ASTRAZENECA AB | Modulation of transthyretin expression |
Apr, 2025
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2028 |
| Orphan Drug Exclusivity(ODE-461) | Dec 21, 2030 |
Drugs and Companies using EPLONTERSEN SODIUM ingredient
NCE-1 date: 22 December, 2027
Market Authorisation Date: 21 December, 2023
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
WAINUA (AUTOINJECTOR) family patents
264. Winlevi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8143240 | SUN PHARM | 17α, 21-dihydroxypregnene esters as antiandrogenic agents |
Jan, 2025
(27 days from now) | |
| US9211295 | SUN PHARM | 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents |
May, 2025
(5 months from now) | |
| US8865690 | SUN PHARM | 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents |
Jul, 2025
(7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 26, 2025 |
Drugs and Companies using CLASCOTERONE ingredient
NCE-1 date: 26 August, 2024
Market Authorisation Date: 26 August, 2020
Treatment: Method of treating acne vulgaris with topically applied cortexolone 17a-propionate
Dosage: CREAM
More Information on Dosage
WINLEVI family patents
265. Xalkori patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8785632 | PF PRISM CV | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
Mar, 2025
(2 months from now) | |
| US7230098 | PF PRISM CV | Aminoheteroaryl compounds as protein kinase inhibitors |
Aug, 2025
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 26, 2016 |
| Orphan Drug Exclusivity(ODE) | Aug 26, 2018 |
| Orphan Drug Exclusivity(ODE-15) | Aug 26, 2018 |
| M(M-163) | Sep 14, 2018 |
| Orphan Drug Exclusivity(ODE-111) | Mar 11, 2023 |
| New Indication(I-852) | Jan 14, 2024 |
| New Indication(I-897) | Jul 14, 2025 |
| Orphan Drug Exclusivity(ODE-328) | Jan 14, 2028 |
| Orphan Drug Exclusivity(ODE-407) | Jul 14, 2029 |
Drugs and Companies using CRIZOTINIB ingredient
Market Authorisation Date: 07 September, 2023
Treatment: NA
Dosage: CAPSULE, PELLETS; CAPSULE
More Information on Dosage
XALKORI family patents
266. Xarelto patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7157456 (Pediatric) | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Feb, 2025
(2 months from now) | |
|
US9415053 (Pediatric) | JANSSEN PHARMS | Solid, orally administrable pharmaceutical composition |
May, 2025
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-643) | Nov 04, 2014 |
| New Indication(I-660) | Nov 02, 2015 |
| New Indication(I-661) | Nov 02, 2015 |
| New Indication(I-662) | Nov 02, 2015 |
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
| New Dosing Schedule(D-168) | Oct 27, 2020 |
| New Indication(I-824) | Oct 11, 2021 |
| New Indication(I-810) | Oct 11, 2022 |
| M(M-284) | Mar 10, 2023 |
| New Indication(I-867) | Aug 23, 2024 |
| New Product(NP) | Dec 20, 2024 |
| Pediatric Exclusivity(PED) | Jun 20, 2025 |
Drugs and Companies using RIVAROXABAN ingredient
NCE-1 date: 24 February, 2024
Market Authorisation Date: 11 October, 2018
Treatment: NA
Dosage: TABLET; FOR SUSPENSION
How can I launch a generic of XARELTO before it's drug patent expiration?
More Information on Dosage
XARELTO family patents
267. Xeljanz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE41783 | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-135) | Feb 21, 2017 |
| New Chemical Entity Exclusivity(NCE) | Nov 06, 2017 |
| New Indication(I-761) | Dec 14, 2020 |
| New Indication(I-780) | May 30, 2021 |
| New Product(NP) | Sep 25, 2023 |
| New Patient Population(NPP) | Sep 25, 2023 |
| New Indication(I-879) | Dec 14, 2024 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
NCE-1 date: 06 November, 2016
Market Authorisation Date: 06 November, 2012
Treatment: NA
Dosage: TABLET
How can I launch a generic of XELJANZ before it's drug patent expiration?
More Information on Dosage
XELJANZ family patents
268. Xeljanz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE41783 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-135) | Feb 21, 2017 |
| New Chemical Entity Exclusivity(NCE) | Nov 06, 2017 |
| New Indication(I-761) | Dec 14, 2020 |
| New Indication(I-780) | May 30, 2021 |
| New Product(NP) | Sep 25, 2023 |
| New Patient Population(NPP) | Sep 25, 2023 |
| New Indication(I-879) | Dec 14, 2024 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
Market Authorisation Date: 25 September, 2020
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
XELJANZ family patents
269. Xeljanz Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE41783 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 06, 2017 |
| New Indication(I-761) | Dec 14, 2020 |
| New Indication(I-879) | Dec 14, 2024 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
NCE-1 date: 06 November, 2016
Market Authorisation Date: 23 February, 2016
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
XELJANZ XR family patents
270. Xelstrym patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8591941 | NOVEN PHARMS INC | Transdermal drug delivery device including an occlusive backing |
Oct, 2025
(9 months from now) | |
| US8632802 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic polymers |
Oct, 2025
(9 months from now) | |
| US9034370 | NOVEN PHARMS INC | Device for transdermal administration of drugs including acrylic polymers |
Oct, 2025
(9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 22, 2025 |
Drugs and Companies using DEXTROAMPHETAMINE ingredient
Market Authorisation Date: 22 March, 2022
Treatment: NA
Dosage: SYSTEM
More Information on Dosage
XELSTRYM family patents
271. Xhance patent expiration
XHANCE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7975690 | OPTINOSE US INC | Nasal devices |
Dec, 2025
(1 year, 13 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 18, 2020 |
| New Indication(I-940) | Mar 15, 2027 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 18 September, 2017
Treatment: Method of delivering fluticasone propionate to a nasal airway
Dosage: SPRAY, METERED
More Information on Dosage
XHANCE family patents
272. Xifaxan patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7906542 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2025
(5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7915275 | SALIX PHARMS | Use of polymorphic forms of rifaximin for medical preparations |
Feb, 2025
(2 months from now) | |
| US7906542 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2025
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 24, 2013 |
| Orphan Drug Exclusivity(ODE) | Mar 24, 2017 |
| New Indication(I-709) | May 27, 2018 |
Drugs and Companies using RIFAXIMIN ingredient
Market Authorisation Date: 24 March, 2010
Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults and symptoms thereof.
Dosage: TABLET
How can I launch a generic of XIFAXAN before it's drug patent expiration?
More Information on Dosage
XIFAXAN family patents
273. Xigduo Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-238) | Feb 22, 2022 |
| New Indication(I-841) | Oct 18, 2022 |
| New Patient Population(NPP) | Jun 12, 2027 |
| Pediatric Exclusivity(PED) | Dec 12, 2027 |
Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 28 July, 2017
Treatment: Treatment of type 2 diabetes mellitus
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
XIGDUO XR family patents
274. Xiidra patent expiration
Can you believe XIIDRA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7314938 | BAUSCH AND LOMB INC | Modulators of cellular adhesion |
Mar, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 11, 2021 |
Drugs and Companies using LIFITEGRAST ingredient
NCE-1 date: 11 July, 2020
Market Authorisation Date: 11 July, 2016
Treatment: NA
Dosage: SOLUTION/DROPS
More Information on Dosage
XIIDRA family patents
275. Ximino patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8252776 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(6 months from now) | |
| US8268804 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(6 months from now) | |
| US7790705 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(6 months from now) | |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 11 July, 2012
Treatment: Treatment of acne
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
XIMINO family patents
276. Xtampza Er patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8557291 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Mar, 2025
(3 months from now) | |
| US7771707 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Mar, 2025
(3 months from now) | |
| US8449909 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Mar, 2025
(3 months from now) | |
| US7399488 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
Mar, 2025
(3 months from now) | |
| US8758813 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Jun, 2025
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 26, 2019 |
Drugs and Companies using OXYCODONE ingredient
Market Authorisation Date: 26 April, 2016
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
XTAMPZA ER family patents
277. Xultophy 100/3.6 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
| M(M-242) | Aug 08, 2022 |
Drugs and Companies using INSULIN DEGLUDEC; LIRAGLUTIDE ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 21 November, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
XULTOPHY 100/3.6 family patents
278. Yupelri patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7585879 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 months from now) | |
| US7910608 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10106503 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 months from now) | |
| US7491736 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 months from now) | |
| US7521041 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 months from now) | |
| US7550595 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 months from now) | |
| US11247969 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 months from now) | |
| US8273894 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 months from now) | |
| US10343995 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 months from now) | |
| US8034946 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 months from now) | |
| US8053448 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 09, 2023 |
Drugs and Companies using REVEFENACIN ingredient
NCE-1 date: 09 November, 2022
Market Authorisation Date: 09 November, 2018
Treatment: For the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: SOLUTION
How can I launch a generic of YUPELRI before it's drug patent expiration?
More Information on Dosage
YUPELRI family patents
279. Zetia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7612058 | ORGANON | Methods for inhibiting sterol absorption |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Dec 05, 2011 |
| M(M-109) | Jan 24, 2015 |
Drugs and Companies using EZETIMIBE ingredient
Market Authorisation Date: 25 October, 2002
Treatment: Reduction of elevated plasma sterol and/or stanol levels in a mammal
Dosage: TABLET
How can I launch a generic of ZETIA before it's drug patent expiration?
More Information on Dosage
ZETIA family patents
280. Zokinvy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7838531 | SENTYNL THERAPS INC | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis |
Jul, 2025
(7 months from now) | |
| US8828356 | SENTYNL THERAPS INC | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis |
Oct, 2025
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2025 |
| Orphan Drug Exclusivity(ODE-324) | Nov 20, 2027 |
Drugs and Companies using LONAFARNIB ingredient
NCE-1 date: 20 November, 2024
Market Authorisation Date: 20 November, 2020
Treatment: Reducing the risk of mortality in hutchinson-gilford progeria syndrome (hgps)
Dosage: CAPSULE
More Information on Dosage
ZOKINVY family patents
281. Zolinza patent expiration
Can you believe ZOLINZA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7399787 | MSD SUB MERCK | Methods of treating cancer with HDAC inhibitors |
Feb, 2025
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 06, 2011 |
| Orphan Drug Exclusivity(ODE) | Oct 06, 2013 |
Drugs and Companies using VORINOSTAT ingredient
NCE-1 date: 06 October, 2010
Market Authorisation Date: 06 October, 2006
Treatment: Treatment of cutaneous manifestations in patients with cutaneous t-cell lymphoma (ctcl)
Dosage: CAPSULE
More Information on Dosage
ZOLINZA family patents
282. Zometa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8324189 | NOVARTIS | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
May, 2025
(5 months from now) | |
|
US8324189 (Pediatric) | NOVARTIS | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
Nov, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Sep 20, 2011 |
Drugs and Companies using ZOLEDRONIC ACID ingredient
Market Authorisation Date: 20 August, 2001
Treatment: Hypercalcemia of malignancy
Dosage: INJECTABLE
How can I launch a generic of ZOMETA before it's drug patent expiration?
More Information on Dosage
ZOMETA family patents
283. Zuragard patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9011897 | ZUREX PHARMA | Catheter lock solution comprising citrate and a paraben |
Feb, 2025
(a month from now) | |
| US8226971 | ZUREX PHARMA | Catheter lock solution comprising citrate and a paraben |
May, 2025
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 26, 2022 |
| M(M-268) | Jun 24, 2024 |
Drugs and Companies using ISOPROPYL ALCOHOL ingredient
Market Authorisation Date: 26 April, 2019
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
ZURAGARD family patents
284. Zurampic patent expiration
Can you believe ZURAMPIC received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8003681 | IRONWOOD PHARMS INC | 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester |
Aug, 2025
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2020 |
Drugs and Companies using LESINURAD ingredient
NCE-1 date: 23 December, 2019
Market Authorisation Date: 22 December, 2015
Treatment: NA
Dosage: TABLET
More Information on Dosage
ZURAMPIC family patents
285. Zydelig patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE44638 | GILEAD SCIENCES INC | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
Aug, 2025
(7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9149477 | GILEAD SCIENCES INC | 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta |
May, 2025
(4 months from now) | |
| US8980901 | GILEAD SCIENCES INC | 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta |
May, 2025
(4 months from now) | |
| USRE44599 | GILEAD SCIENCES INC | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
Jul, 2025
(7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2019 |
| Orphan Drug Exclusivity(ODE) | Jul 23, 2021 |
| Orphan Drug Exclusivity(ODE-70) | Jul 23, 2021 |
| Orphan Drug Exclusivity(ODE-71) | Jul 23, 2021 |
Drugs and Companies using IDELALISIB ingredient
NCE-1 date: 23 July, 2018
Market Authorisation Date: 23 July, 2014
Treatment: Inhibition on pi3k kinase; For the treatment of patients with cll, fl, or sll
Dosage: TABLET
How can I launch a generic of ZYDELIG before it's drug patent expiration?
More Information on Dosage
ZYDELIG family patents
List of large molecules
1. List of Prolia And Xgeva large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US7364736 | AMGEN INC. | Antibodies to OPGL |
Feb, 2025
(2 months from now) | |
| US7427659 | AMGEN INC. | Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction |
Mar, 2025
(2 months from now) |
Ingredients: DENOSUMAB
2. List of Avastin large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US7485704 | GENENTECH, INC. | Reducing protein A leaching during protein A affinity chromatography |
Mar, 2025
(2 months from now) |
Ingredients: BEVACIZUMAB
3. List of Actemra large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US8734800 | GENENTECH, INC. | Subtypes of humanized antibody against interleukin-6 receptor |
Mar, 2025
(3 months from now) | |
| US9902777 | GENENTECH, INC. | Methods for producing subtypes of humanized antibody against interleukin-6 receptor |
May, 2025
(5 months from now) |
Ingredients: TOCILIZUMAB
4. List of Humira large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US8986693 | ABBVIE INC. | Use of TNFα inhibitor for treatment of psoriasis |
Apr, 2025
(3 months from now) | |
| US8961973 | ABBVIE INC. | Multiple-variable dose regimen for treating TNFα-related disorders |
Apr, 2025
(3 months from now) | |
| US8961974 | ABBVIE INC. | Multiple-variable dose regimen for treating TNFα-related disorders |
Apr, 2025
(3 months from now) | |
| US9512216 | ABBVIE INC. | Use of TNFα inhibitor |
Apr, 2025
(3 months from now) | |
| US9061005 | ABBVIE INC. | Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease |
Apr, 2025
(3 months from now) | |
| US9187559 | ABBVIE INC. | Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease |
Apr, 2025
(3 months from now) |
Ingredients: ADALIMUMAB
5. List of Rituxan large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US7976838 | GENENTECH, INC. | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-α inhibitor |
Jun, 2025
(6 months from now) |
Ingredients: RITUXIMAB
6. List of Xolair large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10034940 | GENENTECH, INC. | High concentration antibody and protein formulations |
Nov, 2025
(10 months from now) |
Ingredients: OMALIZUMAB